

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 7
JULY 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 7

July 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

**CUMULATIVE SUPPLEMENT 7
July 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543		
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)		
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)		
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)		
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)		
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	13	22	12		
NUMBER OF APPLICANTS	927	935	957		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
OFIRMEV

+ MALLINCKRODT IP 1000MG/100ML (10MG/ML) N022450 001 Nov 02, 2010 Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
FIORICET

@ ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG;30MG A085868 001 Apr CAHN
AA 300MG;60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG;2.5MG A040846 001 Jun 09, 2010 Feb CTEC
@ SUN PHARM INDS LTD 325MG;10MG A040826 001 Aug 16, 2007 Apr CAHN
NORCO

AA ACTAVIS LABS FL INC 325MG;2.5MG A040148 004 Jul 07, 2014 Feb NEWA
AA 325MG;5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL
DIAMOX

AB + TEVA BRANDED PHARM 500MG N012945 001 Jun CAHN

ACETOHEXAMIDE

TABLET;ORAL
ACETOHEXAMIDE

>A> @ ANI PHARMS INC 250MG A070869 001 Feb 09, 1987 Jul CAHN
>A> @ 500MG A070870 001 Feb 09, 1987 Jul CAHN
>D> @ BARR 250MG A070869 001 Feb 09, 1987 Jul CAHN
>D> @ 500MG A070870 001 Feb 09, 1987 Jul CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA
AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015 Jun NEWA

ACITRETIN

CAPSULE;ORAL
ACITRETIN

AB SIGMAPHARM LABS LLC 10MG A204633 001 May 22, 2015 May NEWA
AB 17.5MG A204633 002 May 22, 2015 May NEWA
AB 22.5MG A204633 003 May 22, 2015 May NEWA
AB 25MG A204633 004 May 22, 2015 May NEWA

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION
TUDORZA PRESSAIR

+ ASTRAZENECA PHARMS 0.375MG/INH N202450 001 Jul 23, 2012 Apr CAHN

ACYCLOVIR

TABLET;ORAL
ACYCLOVIR

AB SUN PHARM INDS LTD 400MG A074980 001 Sep 30, 1998 Apr CAHN
AB 800MG A074980 002 Sep 30, 1998 Apr CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL
 >A> EPIDUO FORTE
 >A> + GALDERMA R AND D 0.3%;2.5% N207917 001 Jul 15, 2015 Jul NEWA

ADENOSINE

INJECTABLE; INJECTION
 ADENOSINE
 AP EUROHLTH INTL SARL 3MG/ML A076500 001 Jun 16, 2004 Jun CAHN
 @ WOCKHARDT 3MG/ML A090220 001 Jul 20, 2009 May DISC

ALBENDAZOLE

TABLET, CHEWABLE; ORAL
 ALBENZA
 + AMEDRA PHARMS LLC 200MG N207844 001 Jun 11, 2015 Jun NEWA

ALBUTEROL SULFATE

POWDER, METERED; INHALATION
 PROAIR RESPICLICK
 + TEVA BRANDED PHARM EQ 0.090MG BASE/INH N205636 001 Mar 31, 2015 Mar NEWA
 SYRUP; ORAL
 ALBUTEROL SULFATE
 AA G AND W LABS INC EQ 2MG BASE/5ML A074454 001 Sep 25, 1995 Apr CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
 COMBIVENT
 @ BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH; 0.018MG/INH N020291 001 Oct 24, 1996 May DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 ALFUZOSIN HYDROCHLORIDE
 @ WOCKHARDT LTD 10MG A090221 001 Aug 10, 2012 Feb DISC
 UROXATRAL
 AB + CONCORDIA PHARMS INC 10MG N021287 001 Jun 12, 2003 Jun CAHN

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL
 TEKAMLO
 @ NOVARTIS EQ 150MG BASE; EQ 5MG BASE N022545 001 Aug 26, 2010 May DISC
 @ EQ 150MG BASE; EQ 10MG BASE N022545 002 Aug 26, 2010 May DISC
 @ EQ 300MG BASE; EQ 5MG BASE N022545 003 Aug 26, 2010 May DISC
 @ EQ 300MG BASE; EQ 10MG BASE N022545 004 Aug 26, 2010 May DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 AMTURNIDE
 @ NOVARTIS EQ 150MG BASE; EQ 5MG BASE; 12.5MG N200045 001 Dec 21, 2010 May DISC
 @ EQ 300MG BASE; EQ 5MG BASE; 12.5MG N200045 002 Dec 21, 2010 May DISC
 @ EQ 300MG BASE; EQ 5MG BASE; 25MG N200045 003 Dec 21, 2010 May DISC
 @ EQ 300MG BASE; EQ 10MG BASE; 12.5MG N200045 004 Dec 21, 2010 May DISC
 @ EQ 300MG BASE; EQ 10MG BASE; 25MG N200045 005 Dec 21, 2010 May DISC

ALMOTRIPTAN MALATE

TABLET; ORAL
 ALMOTRIPTAN MALATE
 AB TEVA PHARMS USA EQ 6.25MG BASE A078027 001 Jul 07, 2015 Jun NEWA
 AB EQ 12.5MG BASE A078027 002 Jul 07, 2015 Jun NEWA
 AXERT
 AB JANSSEN PHARMS EQ 6.25MG BASE N021001 001 May 07, 2001 Jun CFTG
 AB + EQ 12.5MG BASE N021001 002 May 07, 2001 Jun CFTG

ALOSETRON HYDROCHLORIDE

TABLET; ORAL
 ALOSETRON HYDROCHLORIDE
 AB ROXANE EQ 0.5MG BASE A200652 001 May 04, 2015 Apr NEWA
 AB EQ 1MG BASE A200652 002 May 04, 2015 Apr NEWA
 LOTRONEX
 AB PROMETHEUS LABS EQ 0.5MG BASE N021107 002 Dec 23, 2003 Apr CFTG
 AB + EQ 1MG BASE N021107 001 Feb 09, 2000 Apr CFTG

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM

>A>	@ ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul CAHN
>A>	@	0.5MG	A074085	002	Feb 16, 1994	Jul CAHN
>A>	@	1MG	A074085	003	Feb 16, 1994	Jul CAHN
>A>	@	2MG	A074085	004	Feb 26, 1996	Jul CAHN
>A> AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul NEWA
>A> AB		0.5MG	A203346	002	Jul 31, 2015	Jul NEWA
>A> AB		1MG	A203346	003	Jul 31, 2015	Jul NEWA
>A> AB		2MG	A203346	004	Jul 31, 2015	Jul NEWA
AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar NEWA
AB		0.5MG	A200739	002	Apr 15, 2015	Mar NEWA
AB		1MG	A200739	003	Apr 15, 2015	Mar NEWA
AB		2MG	A200739	004	Apr 15, 2015	Mar NEWA
>D>	@ TEVA	0.25MG	A074085	001	Feb 16, 1994	Jul CAHN
>D>	@	0.5MG	A074085	002	Feb 16, 1994	Jul CAHN
>D>	@	1MG	A074085	003	Feb 16, 1994	Jul CAHN
>D>	@	2MG	A074085	004	Feb 26, 1996	Jul CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May CAHN
--------------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar CAHN
@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>A> AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul NEWA
--------	----------------------	-----	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE; INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb DISC
-------------------	----------------	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML; 35MG/100ML	N020177	001	Oct 23, 1995	Feb DISC
-------------------	--	---------	-----	--------------	----------

AMINOCAPROIC ACID

SYRUP; ORAL

AMINOCAPROIC ACID

AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May CAHN
----	----------------	------------	---------	-----	--------------	----------

TABLET; ORAL

AMINOCAPROIC

AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May CAHN
----	----------------	-------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

>A>	@ HERITAGE PHARMS INC	EQ 12.5MG BASE; 5MG	N016949	001		Jul CAHN
>D>	@ VALEANT PHARM INTL	EQ 12.5MG BASE; 5MG	N016949	001		Jul CAHN
	LIMBITROL DS					
>A>	@ HERITAGE PHARMS INC	EQ 25MG BASE; 10MG	N016949	002		Jul CAHN
>D>	@ VALEANT PHARM INTL	EQ 25MG BASE; 10MG	N016949	002		Jul CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar CAHN
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar CAHN
>A>	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Jul NEWA
>A>		EQ 5MG BASE	A204900	002	Jul 23, 2015	Jul NEWA
>A>		EQ 10MG BASE	A204900	003	Jul 23, 2015	Jul NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr CAHN
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr CAHN
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May NEWA
AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	May NEWA
AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May NEWA
AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May NEWA
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May NEWA
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May NEWA
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May NEWA
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May NEWA
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May NEWA
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May NEWA
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May CAIN
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May CAIN
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May CAIN
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May CAIN
AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015	May NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015	May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD 200MG/5ML
@ 400MG/5ML

A065113	001	Nov 29, 2002	Apr CAHN
A065113	002	Nov 29, 2002	Apr CAHN

TABLET;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr CAHN
	@	200MG	A065060	001	Nov 29, 2000	Apr CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
	@	400MG	A065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr CAHN
AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar CTNA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

	@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr CAHN
--	--------------------	---------------------------	---------	-----	--	----------

ANASTROZOLETABLET; ORAL
ANASTROZOLE

@ KREMERS URBAN PHARMS 1MG A091331 001 Jan 05, 2011 Mar CAHN

ARGATROBANINJECTABLE; INJECTION
ARGATROBANAP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML) N201811 001 Mar 23, 2015 Apr CDFR
INJECTABLE; IV (INFUSION)AP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML) N201811 001 Mar 23, 2015 Mar NEWA
ARGATROBANARIPIPIRAZOLETABLET; ORAL
ABILIFYAB OTSUKA 2MG N021436 006 Nov 15, 2002 Apr CFTG
AB + 5MG N021436 005 Nov 15, 2002 Apr CFTG
AB + 10MG N021436 001 Nov 15, 2002 Apr CFTG
AB 15MG N021436 002 Nov 15, 2002 Apr CFTG
AB 20MG N021436 003 Nov 15, 2002 Apr CFTG
AB 30MG N021436 004 Nov 15, 2002 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD 2MG A202101 001 Apr 28, 2015 Apr NEWA
AB 5MG A202101 002 Apr 28, 2015 Apr NEWA
AB 10MG A202101 003 Apr 28, 2015 Apr NEWA
AB 15MG A202101 004 Apr 28, 2015 Apr NEWA
AB 20MG A202101 005 Apr 28, 2015 Apr NEWA
AB 30MG A202101 006 Apr 28, 2015 Apr NEWA
>A> AB APOTEX INC 2MG A078583 001 Jul 24, 2015 Jul NEWA
>A> AB 5MG A078583 002 Jul 24, 2015 Jul NEWA
>A> AB 10MG A078583 003 Jul 24, 2015 Jul NEWA
>A> AB 15MG A078583 004 Jul 24, 2015 Jul NEWA
>A> AB 20MG A078583 005 Jul 24, 2015 Jul NEWA
>A> AB 30MG A078583 006 Jul 24, 2015 Jul NEWA
AB HETERO LABS LTD V 2MG A205064 001 Apr 28, 2015 Apr NEWA
AB 5MG A205064 002 Apr 28, 2015 Apr NEWA
AB 10MG A205064 003 Apr 28, 2015 Apr NEWA
AB 15MG A205064 004 Apr 28, 2015 Apr NEWA
AB 20MG A205064 005 Apr 28, 2015 Apr NEWA
AB 30MG A205064 006 Apr 28, 2015 Apr NEWA
AB TEVA PHARMS USA 2MG A078607 001 Apr 28, 2015 Apr NEWA
AB 5MG A078607 002 Apr 28, 2015 Apr NEWA
AB 10MG A078608 001 Apr 28, 2015 Apr NEWA
AB 15MG A078708 001 Apr 28, 2015 Apr NEWA
AB 20MG A078708 002 Apr 28, 2015 Apr NEWA
AB 30MG A078708 003 Apr 28, 2015 Apr NEWA
AB TORRENT PHARMS LTD 2MG A201519 001 Apr 28, 2015 Apr NEWA
AB 10MG A201519 003 Apr 28, 2015 Apr NEWA
AB 5MG A201519 002 Apr 28, 2015 Apr NEWA
AB 15MG A201519 004 Apr 28, 2015 Apr NEWA
AB 20MG A201519 005 Apr 28, 2015 Apr NEWA
AB 30MG A201519 006 Apr 28, 2015 Apr NEWATABLET, ORALLY DISINTEGRATING; ORAL
ABILIFYAB + OTSUKA 10MG N021729 002 Jun 07, 2006 Apr CFTG
AB 15MG N021729 003 Jun 07, 2006 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD 10MG A202102 001 Apr 28, 2015 Apr NEWA
AB 15MG A202102 002 Apr 28, 2015 Apr NEWAASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN EINJECTABLE; INJECTION
M.V.I.-12 LYOPHILIZED

@ IGI LABS INC 100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL N018933 002 Aug 08, 1985 Jun CAHN

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRIS

	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun CAHN
+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun CAHN

ASPIRIN; BUTALBITAL; CAFFEINECAPSULE;ORAL
FIORINAL

AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan CAHN
----	---	---------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL
FIORINAL

	@	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CAHN
--	---	---------------------	-----------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATECAPSULE;ORAL
FIORINAL W/CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan CAHN
----	---	---------------------	----------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATETABLET;ORAL
NORGESIC

	@	MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar DISC
--	---	---------	-----------------	---------	-----	--------------	----------

NORGESIC FORTE

	@	MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar DISC
--	---	---------	-----------------	---------	-----	--------------	----------

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ

	+		385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar CTEC
--	---	--	-----------------	---------	-----	--------------	----------

	+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar CTEC
--	---	--	-----------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar CAHN
----	--	---------------------	----------------	---------	-----	--------------	----------

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan NEWA
--	---	----------------------	---------------------	---------	-----	--------------	----------

ATENOLOLTABLET;ORAL
ATENOLOL

>A>	AB	ALVOGEN IPCO SARL	25MG	A073646	001	Jul 31, 1992	Jul CAHN
-----	----	-------------------	------	---------	-----	--------------	----------

>A>	AB		50MG	A072303	001	Jul 15, 1988	Jul CAHN
-----	----	--	------	---------	-----	--------------	----------

>A>	AB		100MG	A072304	001	Jul 15, 1988	Jul CAHN
-----	----	--	-------	---------	-----	--------------	----------

@ DAVA PHARMS INC

			25MG	A074099	001	Apr 28, 1992	Jun DISC
--	--	--	------	---------	-----	--------------	----------

>D>	AB	IPR	25MG	A073646	001	Jul 31, 1992	Jul CAHN
-----	----	-----	------	---------	-----	--------------	----------

>D>	AB		50MG	A072303	001	Jul 15, 1988	Jul CAHN
-----	----	--	------	---------	-----	--------------	----------

>D>	AB		100MG	A072304	001	Jul 15, 1988	Jul CAHN
-----	----	--	-------	---------	-----	--------------	----------

TENORMIN

AB		ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
----	--	-------------------	------	---------	-----	--------------	----------

AB			50MG	N018240	001		Feb CAHN
----	--	--	------	---------	-----	--	----------

AB	+		100MG	N018240	002		Feb CAHN
----	---	--	-------	---------	-----	--	----------

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

>A>	AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul CAHN
-----	----	-------------------	-----------	---------	-----	--------------	----------

>A>	AB		100MG;25MG	A072302	001	May 31, 1990	Jul CAHN
-----	----	--	------------	---------	-----	--------------	----------

>D>	AB	IPR	50MG;25MG	A072301	001	May 31, 1990	Jul CAHN
-----	----	-----	-----------	---------	-----	--------------	----------

>D>	AB		100MG;25MG	A072302	001	May 31, 1990	Jul CAHN
-----	----	--	------------	---------	-----	--------------	----------

TENORETIC 100

AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
----	---	-------------------	------------	---------	-----	--------------	----------

TENORETIC 50

AB		ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN
----	--	-------------------	-----------	---------	-----	--------------	----------

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

@	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May DISC
@		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May DISC
@		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May DISC
@		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289	001	Jul 18, 2014	May CRLD
---	-------	----	---------	-----	--------------	----------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
	MOTOFEN HALF-STRENGTH					
@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>A>	@ ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jul CAHN
>D>	@ IVAX PHARMS	0.025MG;2.5MG	A086727	001		Jul CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb NEWA
---	------------	------------------------	---------	-----	--------------	----------

AZELAIC ACID

>A> AEROSOL, FOAM; TOPICAL

>A> FINACEA

>A>	+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015	Jul NEWA
-----	---	----------------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

>A>	AB	BRECKENRIDGE PHARMS	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Jul NEWA
-----	----	---------------------	-----------------------	---------	-----	--------------	----------

AZITHROMYCINFOR SUSPENSION; ORAL
AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May NEWA
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May NEWA

INJECTABLE; INJECTION
AZITHROMYCIN

AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jun NEWA
----	----------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL
AZITHROMYCIN

AB	LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May NEWA
AB		EQ 500MG BASE	A065399	001	May 15, 2015	May NEWA
AB		EQ 600MG BASE	A065400	001	May 15, 2015	May NEWA

BALSALAZIDE DISODIUMCAPSULE; ORAL
COLAZAL

>D>	AB	+ SALIX PHARMS	750MG	N020610	001	Jul 18, 2000	Jul CAHN
>A>	AB	+ VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000	Jul CAHN

TABLET; ORAL
GIAZO

>D>		+ SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012	Jul CAHN
>A>		+ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Jul CAHN

BENAZEPRIL HYDROCHLORIDETABLET; ORAL
BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB		10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB		20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB		40MG	A076820	004	Feb 03, 2006	Jan CAHN
AB	SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
AB		10MG	A076344	002	Feb 11, 2004	Apr CAHN
AB		20MG	A076344	003	Feb 11, 2004	Apr CAHN
AB		40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDETABLET; ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
AB		10MG; 12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
AB		20MG; 12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
AB		20MG; 25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATECAPSULE; ORAL
BENZONATATE

AA	APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA	
AA		200MG	A091310	002	Jan 16, 2015	Jan NEWA	
AA	BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN	
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN	
>A>	AA	CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
>A>	AA	STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Jul NEWA
>A>	AA		200MG	A091133	002	Jul 30, 2015	Jul NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL; TOPICAL
ACANYA

AB	+ DOW PHARM	2.5%; EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG
		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				
AB	ACTAVIS LABS UT INC	2.5%; EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA
		ONEXTON				
	+ DOW PHARM	3.75%; EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZPHETAMINE HYDROCHLORIDETABLET; ORAL
BENZPHETAMINE HYDROCHLORIDE

AA	+ KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun CRLD
		DIDREX				
	@ PHARMACIA AND UPJOHN	50MG	N012427	002		Jun DISC

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar	NEWA
AA		1MG	A204713	002	Apr 14, 2015	Mar	NEWA
AA		2MG	A204713	003	Apr 14, 2015	Mar	NEWA

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr	CAHN
	@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr	CAHN

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar	CAHN
AA		10MG	A091256	002	May 04, 2010	Mar	CAHN
AA		25MG	A091256	003	May 04, 2010	Mar	CAHN
AA		50MG	A091256	004	May 04, 2010	Mar	CAHN
AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb	CMFD
AA		50MG	A040677	001	Mar 27, 2008	Feb	CMFD
	DUVOID						
AA	WELLSPRING PHARM	10MG	A086262	001		Jan	CMFD
AA		25MG	A086263	001		May	CMFD
AA		50MG	A085882	003		May	CMFD

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun	CMFD
	@	75MG	A203174	001	Aug 12, 2014	Jan	CAHN
	TARGRETIN						
AB	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun	CTEC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	APOTEX INC	50MG	A200274	001	May 21, 2015	May	NEWA
AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May	NEWA

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr	NEWA
>A>	AT APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul	NEWA
AT	+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr	CTEC
	+	0.03%	A203991	001	Feb 20, 2015	Mar	CTEC
AT	+	0.03%	A203991	001	Feb 20, 2015	Feb	NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

>D>	+ FOREST LABS INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul	CAHN
>A>	+ FOREST LABS LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul	CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

AP	+ MEDICINES CO	250MG/VIAL	N020873	001	Dec 15, 2000	Jun	CFTG
	BIVALIRUDIN						
AP	HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun	NEWA
AP		250MG/VIAL	A090816	001	Jul 14, 2015	Jun	NEWA

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

+	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun CRLD
		EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun CRLD

>A> BREXPIPIRAZOLE

>A> TABLET; ORAL

>A> REXULTI

>A>	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015	Jul NEWA
>A>		0.5MG	N205422	002	Jul 10, 2015	Jul NEWA
>A>		1MG	N205422	003	Jul 10, 2015	Jul NEWA
>A>		2MG	N205422	004	Jul 10, 2015	Jul NEWA
>A>		3MG	N205422	005	Jul 10, 2015	Jul NEWA
>A>	+	4MG	N205422	006	Jul 10, 2015	Jul NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

AT2	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May CTEC
		BROMFENAC SODIUM					
AT2		APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May CTEC
AT1	+	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May CRLD
AT2		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan NEWA

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

+	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr CAHN
	SPRAY, METERED; NASAL					
	BUDESONIDE					
	APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar CTEC

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP		EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun CAHN
----	--	--------------------	-----------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

>A> AP		PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul NEWA
		TABLET; SUBLINGUAL					
		BUPRENORPHINE HYDROCHLORIDE					
AB		ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb NEWA
AB			EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb NEWA
AB		MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb NEWA
AB			EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb NEWA
AB		SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May NEWA
AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

ZUBSOLV

OREXO AB	EQ 2.9MG BASE; EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun NEWA
----------	-------------------------------	---------	-----	--------------	----------

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
		348MG	N022108	002	Apr 23, 2008	Feb CAHN
+		522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May NEWA
AB1		150MG	A202304	002	May 26, 2015	May NEWA
AB1		200MG	A202304	003	May 26, 2015	May NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May DISC
@	150MG	A201331	002	Aug 30, 2012	May DISC
@	200MG	A201331	003	Aug 30, 2012	May DISC

BUTABARBITAL SODIUM

>D>	ELIXIR;ORAL				
>D>	BUTISOL SODIUM				
>D>	+ MEDA PHARMS	30MG/5ML	A085380	001	Jul DISC
>A>	@	30MG/5ML	A085380	001	Jul DISC
	TABLET;ORAL				
	BUTISOL SODIUM				
	@ MEDA PHARMS	50MG	N000793	003	May DISC

BUTOCONAZOLE NITRATE

	CREAM;VAGINAL				
	BUTOCONAZOLE NITRATE				
	@ ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997 May CTNA
	GYNAZOLE-1				
	+ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012 Jun CTNA

CALCIPOTRIENE

	CREAM;TOPICAL				
	CALCIPOTRIENE				
AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015 May NEWA

CALCITONIN SALMON

	INJECTABLE;INJECTION				
	CALCITONIN-SALMON				
	@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995 Mar CAHN

CALCITRIOL

	CAPSULE;ORAL				
	CALCITRIOL				
AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013 Jan CAHN
AB		0.5MCG	A091174	002	May 24, 2013 Jan CAHN
AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014 Jan CAHN
AB		0.5MCG	A091356	002	Dec 12, 2014 Jan CAHN
	INJECTABLE;INJECTION				
	CALCIJEX				
	@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986 Jun DISC
	@	0.002MG/ML	N018874	002	Sep 25, 1986 Jun DISC
	CALCITRIOL				
	@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008 Jun DISC
	@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002 Jun DISC
	@	0.002MG/ML	A075836	002	Dec 31, 2002 Jun DISC
	@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003 Jun DISC
	@	0.002MG/ML	A075766	002	Feb 20, 2003 Jun DISC
	@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003 Jun DISC
	@	0.002MG/ML	A075746	002	Sep 26, 2003 Jun DISC
	@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006 Jun DISC

CALCIUM ACETATE

	CAPSULE;ORAL				
	CALCIUM ACETATE				
AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015 Jun NEWA
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015 Jun NEWA
	TABLET;ORAL				
	CALCIUM ACETATE				
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015 Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

	INJECTABLE;INJECTION				
	PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER				
	+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008 Jan CPOT
	PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER				
	@ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4	N021703	012	Oct 10, 2008 Jan CPOT

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER							
GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)							
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan	CPOT
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan	CPOT
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan	CPOT
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 0/0 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan	CPOT
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan	CPOT
<u>CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE</u>							
INJECTABLE; INJECTION							
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187	N207026	002	Jan 13, 2015	Jan	NEWA

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

GM/1000ML (5000ML)

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML; 3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan NEWA
---	---------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

@ ALCON PHARMS LTD

0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML

N022193 001 Jul 24, 2008 Jun DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML

N017390 001

Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML

N017438 001

Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb CAIN
---	---------------	---	---------	-----	--------------	----------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML	N207026	001	Jan 13, 2015	Feb CAIN
---	---------------	---	---------	-----	--------------	----------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG;12.5MG	A204100	001	Feb 27, 2015	Feb NEWA
AB		32MG;12.5MG	A204100	002	Feb 27, 2015	Feb NEWA
AB		32MG;25MG	A204100	003	Feb 27, 2015	Feb NEWA

CANGRELOR

POWDER;IV (INFUSION)

KENGREAL

+	MEDICNES CO	50MG/VIAL	N204958	001	Jun 22, 2015	Jun NEWA
---	-------------	-----------	---------	-----	--------------	----------

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET;ORAL

CAPOTEN

@ PAR PHARM

12.5MG

N018343 005 Jan 17, 1985 May DISC

@

25MG

N018343 002 May DISC

@

50MG

N018343 001 May DISC

@

100MG

N018343 003 May DISC

CAPTOPRIL

>A>	@ G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996	Jul CAHN
	@	12.5MG	A074462	001	Feb 13, 1996	Apr CAHN
>A>	@	12.5MG	A074483	001	Feb 13, 1996	Jul CAHN
	@	12.5MG	A074590	004	Aug 30, 1996	Apr CAHN

TABLET; ORAL
CAPTOPRIL

>A>	@	25MG	A074433	002	Feb 13, 1996	Jul CAHN
	@	25MG	A074462	002	Feb 13, 1996	Apr CAHN
>A>	@	25MG	A074483	002	Feb 13, 1996	Jul CAHN
	@	25MG	A074590	002	Aug 30, 1996	Apr CAHN
>A>	@	50MG	A074433	003	Feb 13, 1996	Jul CAHN
	@	50MG	A074462	003	Feb 13, 1996	Apr CAHN
>A>	@	50MG	A074483	003	Feb 13, 1996	Jul CAHN
	@	50MG	A074590	001	Aug 30, 1996	Apr CAHN
>A>	@	100MG	A074433	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074462	004	Feb 13, 1996	Apr CAHN
>A>	@	100MG	A074483	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074590	003	Aug 30, 1996	Apr CAHN
AB	+	MYLAN	A074434	004	Feb 13, 1996	May CRLD
>D>	@	TEVA	A074433	001	Feb 13, 1996	Jul CAHN
>D>	@	12.5MG	A074483	001	Feb 13, 1996	Jul CAHN
>D>	@	25MG	A074433	002	Feb 13, 1996	Jul CAHN
>D>	@	25MG	A074483	002	Feb 13, 1996	Jul CAHN
>D>	@	50MG	A074433	003	Feb 13, 1996	Jul CAHN
>D>	@	50MG	A074483	003	Feb 13, 1996	Jul CAHN
>D>	@	100MG	A074433	004	Feb 13, 1996	Jul CAHN
>D>	@	100MG	A074483	004	Feb 13, 1996	Jul CAHN

CAPTAPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB		200MG	A076697	002	May 20, 2011	May CAHN
AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL
RYTARY

	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA
	SUSPENSION; ENTERAL					
	DUOPA					
+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA		350MG	A205126	002	Jul 08, 2015	Jun NEWA
	SOMA					
AB	+	MEDA PHARMS	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL

TABLET; ORAL
CARVEDILOL

	@	HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
	@		6.25MG	A077887	002	Sep 07, 2007	Jun DISC
	@		12.5MG	A077887	003	Sep 07, 2007	Jun DISC
	@		25MG	A077887	004	Sep 07, 2007	Jun DISC
AB		SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB			6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB			12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB			25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL

CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

@ IGI LABS INC

@

@

@

@

CEFOTAN IN PLASTIC CONTAINER

@ IGI LABS INC

@

EQ 1GM BASE/VIAL
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIAL

A063293	001	Apr 29, 1993	May CAHN
N050588	001	Dec 27, 1985	Mar CAHN
A063293	002	Apr 29, 1993	May CAHN
N050588	002	Dec 27, 1985	Mar CAHN
N050588	003	Apr 25, 1988	Mar CAHN
N050694	002	Jul 30, 1993	Mar CAHN
N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIME

INJECTABLE;INJECTION

FORTAZ

AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

@ CONCORDIA PHARMS INC

+

+

EQ 10MG BASE/ML
EQ 20MG BASE/ML
EQ 40MG BASE/ML

N050634	001	Apr 28, 1989	Jun CAHN
N050634	002	Apr 28, 1989	Jun CAHN
N050634	003	Apr 28, 1989	Jun CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
----	-------------	-------------------	---------	-----	--------------	----------

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

@ FACTA FARMA

@

FRESENIUS KABI USA

@

EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 250MG BASE/VIAL
EQ 250MG BASE/VIAL

A065268	001	Feb 28, 2007	Jan CAHN
A065268	002	Feb 28, 2007	Jan CAHN
A065245	001	Feb 15, 2006	Jul DISC
A065245	001	Feb 15, 2006	Jul DISC

>D> AP
>A>

CEFUROXIME AXETILFOR SUSPENSION;ORAL
CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET;ORAL

CEFUROXIME AXETIL

>A>	AB	ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
>A>	AB		EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
	AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
	AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
	AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN
>D>	AB	TEVA	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
>D>	AB		EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN

CEFUROXIME SODIUMINJECTABLE;INJECTION
CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN

ZINACEF

AP	+	CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN

ZINACEF IN PLASTIC CONTAINER

@	CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
----	-------------	--------------------	---------	-----	--------------	----------

ZINACEF

AB	+	CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN
----	---	----------------------	--------------------	---------	-----	--------------	----------

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
AB		100MG	A204197	002	Jun 02, 2015	May NEWA
AB		200MG	A204197	003	Jun 02, 2015	May NEWA
AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
AB		200MG	A202240	003	Jun 09, 2015	May NEWA
AB		400MG	A202240	004	Jun 09, 2015	May NEWA
AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN

FOR SUSPENSION;ORAL

CEPHALEXIN

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CHLOROTHIAZIDE SODIUMINJECTABLE;INJECTION
CHLOROTHIAZIDE SODIUM

AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA
----	---------------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATETABLET, EXTENDED RELEASE;ORAL
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE
SPRIASO LLC 8MG;54.3MG

N206323	001	Jun 22, 2015	Jun NEWA
---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA		TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
		VITUZ					
AA	+	CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AA		COASTAL PHARMS	4MG/5ML; 5MG/5ML; 60MG/5ML	A205657	001	Aug 03, 2015	Jul NEWA
--------	--	----------------	----------------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUZISTRA XR

+		TRIS PHARMA INC	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr NEWA
+		VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

@ CYCLE PHARMS LTD 30MG/ML
 @ 100MG/ML

A088157 001 Apr 27, 1983 Jun CAHN
 A088158 001 Apr 27, 1983 Jun CAHN

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+		EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb CAHN
---	--	--------------------	---------	---------	-----	--	----------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ CYCLE PHARMS LTD 10MG
 @ 25MG
 @ 50MG
 @ 100MG
 @ 200MG
 @ SANDOZ 10MG
 @ 25MG
 @ 50MG
 @ 100MG
 @ 200MG

A085331 001 Jun CAHN
 A085331 002 Jun CAHN
 A085331 003 Jun CAHN
 A085331 004 Jun CAHN
 A085331 005 Jun CAHN
 A080439 001 May DISC
 A080439 002 May DISC
 A080439 003 May DISC
 A080439 004 May DISC
 A080439 005 May DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

		@ G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar CMFD
AB	+	MYLAN	50MG	A086831	001		Jun CTEC
		THALITONE					
		@ CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Jun DISC

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

		ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar NEWA
+			250MG	N205750	002	Mar 17, 2015	Mar NEWA
		RTRX	50MG	N205750	001	Mar 17, 2015	Apr CAHN
+			250MG	N205750	002	Mar 17, 2015	Apr CAHN

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	+	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CRLD
		VISTIDE					
		@ GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ G AND W LABS INC EQ 300MG BASE/5ML A074176 001 Jun 01, 1994 Apr CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION
CIPROFLOXACIN

AP	CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr CAHN
AP		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr CAHN
	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr CAHN
AP		400MG/200ML	A078024	002	Mar 18, 2008	Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL
CIPROFLOXACIN HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr CAHN
AB		EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr CAHN
AB		EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION
CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb NEWA
AP		EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL
CITALOPRAM HYDROBROMIDE

AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr CAHN
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr CAHN
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL
CLARITHROMYCIN

AB	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr CAHN
AB		250MG/5ML	A065382	002	Aug 30, 2007	Apr CAHN

TABLET;ORAL
CLARITHROMYCIN

AB	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr CAHN
AB		500MG	A065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

@ ABBVIE 500MG

N050775 001 Mar 03, 2000 Jan DISC

CLARITHROMYCIN

AB + TEVA 500MG

A065154 001 May 18, 2005 Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION
TIMENTIN

@ GLAXOSMITHKLINE EQ 100MG BASE/VIAL;EQ 3GM
BASE/VIAL

A062691 001 Dec 19, 1986 May DISC

@ EQ 100MG BASE/VIAL;EQ 3GM
BASE/VIAL

N050590 001 Apr 01, 1985 May DISC

@ EQ 200MG BASE/VIAL;EQ 3GM
BASE/VIAL

N050590 002 Apr 01, 1985 May DISC

@ EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL

N050590 003 Aug 18, 1987 May DISC

TIMENTIN IN PLASTIC CONTAINER

@ GLAXOSMITHKLINE EQ 100MG BASE/100ML;EQ 3GM
BASE/100ML

N050658 001 Dec 15, 1989 May DISC

CLEMASTINE FUMARATE

TABLET;ORAL
CLEMASTINE FUMARATE

>A> @ ANI PHARMS INC 1.34MG

A073282 001 Jan 31, 1992 Jul CAHN

>D> @ TEVA 1.34MG

A073282 001 Jan 31, 1992 Jul CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr CAHN
AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr CAHN
AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr CAHN
AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

@ IGI LABS INC EQ 150MG BASE/ML

A062928 001 Feb 13, 1989 Mar CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ BOCA PHARMA LLC EQ 1% BASE

A062944 001 Jan 11, 1989 Jan CAHN

AT VINTAGE PHARMS EQ 1% BASE

A203343 001 May 29, 2015 May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB ACTAVIS MID ATLANTIC 1.2%;0.025%
ZIANA

A202564 001 Jun 12, 2015 Jun NEWA

AB + MEDICIS 1.2%;0.025%

N050802 001 Nov 07, 2006 Jun CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2 + FOUGERA PHARMS 0.05%
CORMAX

A075430 001 May 26, 1999 May CRLD

AB1 + HI TECH PHARMA 0.05%
TEMOVATE

A074220 001 May 16, 1997 Jun CRLD

@ FOUGERA PHARMS 0.05%

N019322 001 Dec 27, 1985 Jun DISC

TEMOVATE E

@ FOUGERA PHARMS 0.05%

N020340 001 Jun 17, 1994 May DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS 0.05%
TEMOVATE

A075368 001 Feb 15, 2000 May CRLD

@ FOUGERA PHARMS 0.05%

N020337 001 Apr 29, 1994 May DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB G AND W LABS INC 0.05%

A074089 001 Feb 16, 1994 Feb CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT G AND W LABS INC 0.05%

A074331 001 Dec 15, 1995 Mar CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

@ EMD SERONO 50MG

N018361 001 Mar 22, 1982 Jun DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB ACTAVIS LABS UT INC 0.1MG/24HR

A090873 001 May 06, 2014 Mar CAHN

AB 0.2MG/24HR

A090873 002 May 06, 2014 Mar CAHN

AB 0.3MG/24HR

A090873 003 May 06, 2014 Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ DAVA PHARMS INC 0.1MG

A071783 001 Apr 05, 1988 May DISC

@ 0.2MG

A071784 001 Apr 05, 1988 May DISC

@ 0.3MG

A071785 001 Apr 05, 1988 May DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2 ACTAVIS ELIZABETH 0.1MG

A202792 001 May 15, 2015 May NEWA

AB1 0.1MG

A203320 001 May 15, 2015 May NEWA

AB2 0.2MG

A202792 002 May 15, 2015 May NEWA

AB1 0.2MG

A203320 002 May 15, 2015 May NEWA

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

AB2	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	May CTEC
AB2		0.2MG	A202983	002	Apr 02, 2014	May CTEC
CLONIDINE HYDROCHLORIDE						
AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May CTEC
AB1		0.2MG	A202984	002	Sep 30, 2013	May CTEC
KAPVAY						
AB1	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
AB1	+	0.1MG	N022331	003	Sep 28, 2010	May CTEC
AB1	+	0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
AB1		0.2MG	N022331	004	Sep 28, 2010	May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL
CLORAZEPATE DIPOTASSIUM

AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr CAHN
AB		7.5MG	A076911	002	Sep 29, 2004	Apr CAHN
AB		15MG	A076911	003	Sep 29, 2004	Apr CAHN

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL
PREZCOBIX

+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA
---	---------------	---------------------	---------	-----	--------------	----------

CODEINE SULFATE

SOLUTION;ORAL
CODEINE SULFATE
@ ROXANE

	30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC
--	----------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL
MITIGARE

HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan CAHN
-------------------	-------	---------	-----	--------------	----------

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION
COLISTIMETHATE SODIUM

AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May NEWA
----	-------------------	--------------------	---------	-----	--------------	----------

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

@ EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb CAHN
----------------------	--------	---------	-----	--	----------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun NEWA
AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr CAHN
AB		7.5MG	A078722	002	May 12, 2008	Apr CAHN
AB		10MG	A078722	003	May 12, 2008	Apr CAHN

DABRAFENIB MESYLATE

CAPSULE;ORAL
TAFINLAR

NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar CAHN
+	EQ 75MG BASE	N202806	002	May 29, 2013	Mar CAHN

>A> DACLATASVIR DIHYDROCHLORIDE

>A> TABLET;ORAL
>A> DAKLINZA

>A>	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jul NEWA
>A>	+	EQ 60MG BASE	N206843	002	Jul 24, 2015	Jul NEWA

DALTEPARIN SODIUM

INJECTABLE;INJECTION
FRAGMIN

@ PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr CAHN

INJECTABLE;SUBCUTANEOUS

FRAGMIN

	Pfizer Inc	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun CAHN
@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun CAHN
@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun CAHN
	Pharmacia and Upjohn	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr CAHN
@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr CAHN
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr CAHN
@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB	Elite Labs Inc	25MG	A076686	001	Oct 24, 2005	May CAHN
AB		50MG	A076686	002	Oct 24, 2005	May CAHN
AB		100MG	A076686	003	Oct 24, 2005	May CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

AB	Anchen Pharms	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB		EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA
	Enablex					
AB	Warner Chilcott LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

AP	+	Otsuka Pharm Co Ltd	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

DEFERASIROX

TABLET;ORAL

JADENU

	Novartis Pharms Corp	90MG	N206910	001	Mar 30, 2015	Mar NEWA
		180MG	N206910	002	Mar 30, 2015	Mar NEWA
+		360MG	N206910	003	Mar 30, 2015	Mar NEWA

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

KYBELLA

+	Kythera Biopharms	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr NEWA
---	-------------------	--------------------	---------	-----	--------------	----------

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS

IPRIVASK

+	Valeant Pharms North	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN
---	----------------------	-----------	---------	-----	--------------	----------

DESLORATADINE

SOLUTION;ORAL

CLARINEX

AA	+	Merck Sharp Dohme	0.5MG/ML	N021300	001	Sep 01, 2004	Jun CFTG
		Desloratadine					
AA		Taro Pharm Inds	0.5MG/ML	A202592	001	Jun 30, 2015	Jun NEWA

DESMOPRESSIN ACETATETABLET; ORAL
DDAVP

AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan CAHN
		DESMOPRESSIN ACETATE					
AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
AB			0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-28
BEKYREE

>A>	AB	LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul NEWA
		ISIBLOOM					
>A>	AB	SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul NEWA
		KARIVA					
AB	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr CTEC
		KIMIDESS					
AB		VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr NEWA

DESONIDECREAM; TOPICAL
DESONIDE

AB		TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May CMFD
----	--	-------------	-------	---------	-----	--------------	----------

DESOXIMETASONECREAM; TOPICAL
DESOXIMETASONE

AB		VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun NEWA
----	--	----------------	-------	---------	-----	--------------	----------

OINTMENT; TOPICAL
DESOXIMETASONE

AB		PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr NEWA
----	--	------------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

AB		ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun NEWA
AB		LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun NEWA
AB		MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun NEWA
AB		SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun NEWA
		PRISTIQ					
AB	+	WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun CFTG
AB	+		EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun CFTG

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
MAXITROL

AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar CAHN
----	---	----------------	---------------------------------------	---------	-----	--	----------

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar CAHN
----	---	----------------	---------------------------------------	---------	-----	--	----------

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE; INJECTION
PRECEDEX

		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan NEWA
--	--	---------	--------------------------------------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

5GM/100ML;30MG/100ML;37MG/100ML;36
8MG/100ML;526MG/100ML;502MG/100ML

N017451 001

Mar DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION

MD-76R

AP + LIEBEL-FLARSHEIM 66%;10%

N019292 001 Sep 29, 1989 Feb CAHN

SOLUTION;ORAL, RECTAL

MD-GASTROVIEW

AA LIEBEL-FLARSHEIM 66%;10%

A087388 001 Jan CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT IGI LABS INC 1.5%

A202769 001 Jul 08, 2015 Jun NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

AA + ACTAVIS LABS UT INC 25MG

N011722 002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

AB + ACTAVIS LABS UT INC 75MG

N012546 001 Mar CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

>A> AB VERSAPHARM INC 0.05%

A206572 001 Jul 24, 2015 Jul NEWA

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB HERITAGE PHARMA 500MG

A202845 001 Mar 08, 2012 Mar CAHN

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

AP EUROHLTH INTL SARL 0.25MG/ML

A083391 001 Feb CAHN

TABLET;ORAL

DIGOXIN

AB MYLAN PHARMS INC 0.125MG

A040282 001 Dec 23, 1999 Jan CTEC

AB 0.25MG

A040282 002 Dec 23, 1999 Jan CTEC

AB SUN PHARM INDS INC 0.125MG

A076363 001 Jan 31, 2003 Feb CMFD

AB 0.25MG

A076363 002 Jan 31, 2003 Feb CMFD

LANOXIN

AB CONCORDIA PHARMS INC 0.0625MG

N020405 001 Sep 30, 1997 Apr CAHN

AB 0.125MG

N020405 002 Sep 30, 1997 Apr CAHN

AB 0.1875MG

N020405 003 Sep 30, 1997 Apr CAHN

AB + 0.25MG

N020405 004 Sep 30, 1997 Apr CAHN

@

AB 0.375MG

N020405 005 Sep 30, 1997 Apr CAHN

@

AB 0.5MG

N020405 006 Sep 30, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB2 + MYLAN 240MG

A075124 001 Mar 18, 1998 Feb CRLD

TIAZAC

AB4 VALEANT PHARMS NORTH 120MG

N020401 001 Sep 11, 1995 Feb CAHN

AB4 180MG

N020401 002 Sep 11, 1995 Feb CAHN

AB4 240MG

N020401 003 Sep 11, 1995 Feb CAHN

AB4 300MG

N020401 004 Sep 11, 1995 Feb CAHN

AB4 360MG

N020401 005 Sep 11, 1995 Feb CAHN

AB4 + 420MG

N020401 006 Oct 16, 1998 Feb CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP EUROHLTH INTL SARL 5MG/ML

A078538 001 Dec 17, 2008 Jun CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP + EUROHLTH INTL SARL 50MG/ML A080817 002 Jun CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP EUROHLTH INTL SARL 5MG/ML A074521 001 Oct 18, 1996 Jun CAHN

DISULFIRAM

TABLET; ORAL
DISULFIRAM

AB MYLAN PHARMS INC 250MG A203916 001 Mar 04, 2015 Feb NEWA
AB 500MG A203916 002 Mar 04, 2015 Feb NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

AB AMNEAL PHARMS EQ 250MG VALPROIC ACID A203730 001 May 29, 2015 May NEWA
AB EQ 500MG VALPROIC ACID A203730 002 May 29, 2015 May NEWA
>A> @ G AND W LABS INC EQ 500MG VALPROIC ACID A078700 001 Aug 03, 2009 Jul CAHN
>D> @ TEVA PHARMS USA EQ 500MG VALPROIC ACID A078700 001 Aug 03, 2009 Jul CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

@ IGI LABS INC EQ 12.5MG BASE/ML A074098 001 Feb 21, 1995 Mar CAHN

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB HETERO LABS LTD V 5MG A203034 001 Jan 30, 2015 Jan NEWA
AB 10MG A203034 002 Jan 30, 2015 Jan NEWA
AB SUN PHARM INDS LTD 5MG A076786 001 Nov 26, 2010 Apr CAHN
AB 10MG A076786 002 Nov 26, 2010 Apr CAHN
AB 23MG A204293 001 Jun 05, 2015 May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
NAMZARIC

FOREST LABS LLC 10MG; 14MG N206439 001 Dec 23, 2014 Mar CAHN
+ 10MG; 28MG N206439 002 Dec 23, 2014 Mar CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

@ IGI LABS INC 40MG/ML A070087 001 Oct 23, 1985 Mar CAHN
@ 40MG/ML N018656 001 Jun 28, 1983 Mar CAHN
@ 80MG/ML A070089 001 Oct 23, 1985 Mar CAHN
@ 80MG/ML A070090 001 Oct 23, 1985 Mar CAHN
@ 80MG/ML A070091 001 Oct 23, 1985 Mar CAHN
@ 160MG/ML A070092 001 Oct 23, 1985 Mar CAHN
@ 160MG/ML A070093 001 Oct 23, 1985 Mar CAHN
@ 160MG/ML A070094 001 Oct 23, 1985 Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOPRAM

AP + EUROHLTH INTL SARL 20MG/ML N014879 001 Jun CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HYDROCHLORIDE

AB + MYLAN PHARMS INC EQ 100MG BASE A070791 005 May 13, 1986 Jan CRLD
+ PAR PHARM EQ 150MG BASE A071669 001 Nov 09, 1987 Jan CRLD
CREAM; TOPICAL
ZONALON
+ DELCOR ASSET CORP 5% N020126 001 Apr 01, 1994 Mar CAHN

DOXERCALCIFEROL

INJECTABLE; INJECTION
DOXERCALCIFEROL

AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA
----	-----------	--------------------	---------	-----	--------------	-----	------

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA
AB		EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN

TABLET; ORAL

DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION
DOXYCYCLINE

@	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar	CAHN
@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar	CAHN
@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar	CAHN

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar	CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar	CRLD

EDOXABAN TOSYLATE

TABLET; ORAL

SAVAYSA

	DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan	NEWA
		EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan	NEWA
+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan	NEWA

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar	CRLD
	TENSILON						
@	IGI LABS INC	10MG/ML	N007959	001		Apr	CAHN
@	VALEANT PHARMS	10MG/ML	N007959	001		Mar	DISC
	TENSILON PRESERVATIVE FREE						
@	IGI LABS INC	10MG/ML	N007959	002		Apr	CAHN
@	VALEANT PHARMS	10MG/ML	N007959	002		Mar	DISC

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

	NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar	CAHN
		EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar	CAHN
		EQ 50MG ACID	N022291	002	Nov 20, 2008	May	CRLD
+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar	CAHN
+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May	CRLD
		EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar	CAHN
+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May	CRLD
		EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar	CAHN

ELUXADOLINETABLET; ORAL
VIBERZI

>A>	FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul CAHN
>A>	+	100MG	N206940	002	May 27, 2015	Jul CAHN
>D>	FURIEX PHARMS	75MG	N206940	001	May 27, 2015	Jul CAHN
		75MG	N206940	001	May 27, 2015	May NEWA
>D>	+	100MG	N206940	002	May 27, 2015	Jul CAHN
	+	100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTINTABLET; ORAL
GLYXAMBIBOEHRINGER INGELHEIM 10MG; 5MG
+ 25MG; 5MG

N206073	001	Jan 30, 2015	Jan NEWA
N206073	002	Jan 30, 2015	Jan NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	SANDOZ INC	2.5MG
AB		5MG
AB		10MG
AB		20MG
	@ SUN PHARM INDS LTD	2.5MG
	@	5MG
	@	10MG
	@	20MG

A075496	001	Aug 22, 2000	Mar CMFD
A075496	002	Aug 22, 2000	Mar CMFD
A075459	001	Aug 22, 2000	Mar CMFD
A075459	002	Aug 22, 2000	Mar CMFD
A075556	001	Aug 22, 2000	Apr CAHN
A075556	002	Aug 22, 2000	Apr CAHN
A075556	003	Aug 22, 2000	Apr CAHN
A075556	004	Aug 22, 2000	Apr CAHN

VASOTEC

AB	VALEANT PHARMS NORTH	2.5MG
AB		5MG
AB		10MG
AB	+	20MG

N018998	005	Jul 26, 1988	Apr CAHN
N018998	001	Dec 24, 1985	Apr CAHN
N018998	002	Dec 24, 1985	Apr CAHN
N018998	003	Dec 24, 1985	Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	5MG; 12.5MG
AB		10MG; 25MG

A075727	001	Sep 18, 2001	Apr CAHN
A075727	002	Sep 18, 2001	Apr CAHN

ENTACAPONE

TABLET; ORAL

ENTACAPONE

AB	AUROBINDO PHARMA LTD	200MG
----	----------------------	-------

A203437	001	Jun 19, 2015	Jun NEWA
---------	-----	--------------	----------

>A> EPINEPHRINE

>A>	INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
>A>	ADRENALIN

>A>	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN
>A>		INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS					
>A>		ADRENALIN					
>A>	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN

>D> EPINEPHRINE HYDROCHLORIDE

>D>	INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
>D>	ADRENALIN

>D>	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN
>D>		INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS					
>D>		ADRENALIN					
>D>	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

@ ABBVIE 600MG; 12.5MG
@ 600MG; 25MG

N021268	001	Nov 01, 2001	Jun DISC
N021268	002	Nov 01, 2001	Jun DISC

EPTIFIBATIDEINJECTABLE;INJECTION
EPTIFIBATIDE

AP	TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun NEWA
AP		75MG/100ML	A091555	001	Jun 05, 2015	May NEWA
INTEGRILIN						
AP	+ SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun CTEC
AP	+	75MG/100ML	N020718	002	May 18, 1998	May CFTG

ERGOCALCIFEROLCAPSULE;ORAL
VITAMIN D

AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan CAHN
----	----------------------	-----------	---------	-----	--	----------

ERYTHROMYCIN ESTOLATESUSPENSION;ORAL
ERYTHROMYCIN ESTOLATE

	@ G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr CAHN
	@	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATEGRANULE;ORAL
ERYTHROMYCIN ETHYLSUCCINATE

>A>	@ ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001		Jul CAHN
>D>	@ BARR	EQ 200MG BASE/5ML	A062055	001		Jul CAHN

ESCITALOPRAM OXALATESOLUTION;ORAL
ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	May NEWA
----	-------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL
ESCITALOPRAM OXALATE

AB	MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr NEWA
AB		EQ 10MG BASE	A077550	002	May 14, 2015	Apr NEWA
AB		EQ 20MG BASE	A077550	003	May 14, 2015	Apr NEWA

ESMOLOL HYDROCHLORIDEINJECTABLE;INJECTION
ESMOLOL HYDROCHLORIDE

>A>	AP AUROBINDO PHARMA LTD	10MG/ML	A205520	001	Jul 23, 2015	Jul NEWA
	AP LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb NEWA

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan NEWA
AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan NEWA
>A>	AB MYLAN LABS LTD	EQ 20MG BASE	A078936	001	Aug 02, 2015	Jul NEWA
>A>	AB	EQ 40MG BASE	A078936	002	Aug 03, 2015	Jul NEWA
NEXIUM						
AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan CFTG
AB	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan CFTG

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

MINIVELLE

NOVEN 0.025MG/24HR

N203752 005 Sep 23, 2014 Jan NEWA

TABLET;VAGINAL

ESTRADIOL

@ AMNEAL PHARMS 10MCG

A205256 001 May 29, 2015 May DISC

ESZOPICLONETABLET; ORAL
ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan NEWA

ETHACRYNATE SODIUMINJECTABLE; INJECTION
EDECIN

>D>	+	ATON	EQ 50MG BASE/VIAL	N016093	001		Jul CFTG
>A>	AP	+	EQ 50MG BASE/VIAL	N016093	001		Jul CFTG
>A>		ETHACRYNATE SODIUM					
>A>	AP	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Jul NEWA

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL
ETHAMBUTOL HYDROCHLORIDE

AB	VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan CMFD
AB		400MG	A075095	002	Nov 30, 1999	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
ASHLYNA

AB	GLENMARK GENERICS	0.03MG; 0.01MG; 0.15MG, N/A	A203163	001	Feb 23, 2015	Feb NEWA	
	LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB	GLENMARK GENERICS	0.02MG; 0.09MG	A202791	001	Apr 09, 2015	Mar NEWA	
AB	GLENMARK PHARMS LTD	0.03MG; 0.15MG	A203164	001	Jun 12, 2015	Jun NEWA	
AB	+	WATSON LABS	0.02MG; 0.09MG	A079218	001	Jun 06, 2011	Mar CTEC

TABLET; ORAL-28
VIENVA

AB1	SANDOZ INC	0.02MG; 0.1MG	A201088	001	May 21, 2015	May NEWA
-----	------------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE; TRANSDERMAL
ORTHO EVRA

	@	JANSSEN PHARMS	0.035MG/24HR; 0.15MG/24HR	N021180	001	Nov 20, 2001	Feb DISC
		XULANE					
AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR; 0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

	@	ACTAVIS LABS UT INC	0.035MG; 0.5MG	N017566	001		Mar CAHN
		NORINYL 1+35 21-DAY					

AB		ACTAVIS LABS UT INC	0.035MG; 1MG	N017565	001		Feb CAHN
		TRI-NORINYL 21-DAY					
	@	ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	001	Apr 13, 1984	Feb CAHN

TABLET; ORAL-28

BREVICON 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG; 0.5MG	N017743	001		Mar CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL					

>D>	AB	FAMY CARE LTD	0.035MG; 0.4MG	A200897	001	May 11, 2015	Jul CRLD
	AB		0.035MG; 0.4MG	A200897	001	May 11, 2015	Apr NEWA
>D>	AB	+	0.05MG; 1MG	A203006	001	Aug 05, 2013	Jul CTEC
>A>	AB	+	JAI PHARMA LTD	0.035MG; 0.4MG	A200897	001	May 11, 2015
>A>		+	0.05MG; 1MG	A203006	001	Aug 05, 2013	Jul CTEC

AB		ACTAVIS LABS UT INC	0.035MG; 1MG	N017565	002		Feb CAHN
		OVCON-35					

>D>	AB	+	WARNER CHILCOTT LLC	0.035MG; 0.4MG	N017716	001	Jul DISC
>A>		@	0.035MG; 0.4MG	N017716	001		Jul DISC
		TRI-NORINYL 28-DAY					

AB	+	ACTAVIS LABS UT INC	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N018977	002	Apr 13, 1984	Feb CAHN
----	---	---------------------	--	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATETABLET; ORAL
FEMHRT

AB	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar CTEC
	LARIN 24 FE					
AB	NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
AB	+ BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar CTEC
AB	GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar NEWA
AB		0.005MG;1MG	A203038	002	Apr 02, 2015	Mar NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	+ AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.2	A200383	001	Apr 07, 2015	Mar NEWA
		15MG;0.25MG				
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar NEWA
	TRI-LO-ESTARYLLA					
AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A091232	001	Jun 29, 2015	Jun NEWA
		15MG,0.25MG				

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

LOW-OGESTREL-28

AB	WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb CMFD
----	-------------	--------------	---------	-----	--------------	----------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

@ ORGANON USA INC

68MG/IMPLANT

N021529 001 Jul 17, 2006 Jun DISC

EZETIMIBE

TABLET; ORAL

EZETIMIBE

	@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun DISC
AB		10MG	A078560	001	Jun 26, 2015	Jun NEWA
	ZETIA					
	+ MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun CTEC
AB	+	10MG	N021445	001	Oct 25, 2002	Jun CFTG

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	+ EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun CAHN
	FAMOTIDINE PRESERVATIVE FREE					
AP	+ EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun CAHN

TABLET; ORAL

PEPCID

AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
AB	+	40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA
AB		5MG	A203032	002	May 21, 2015	May NEWA
AB		10MG	A203032	003	May 21, 2015	May NEWA
AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN
AB		5MG	A091200	002	Dec 13, 2013	Apr CAHN
AB		10MG	A091200	003	Dec 13, 2013	Apr CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr	CAHN
AB		130MG	A201748	002	Oct 31, 2014	Apr	CAHN

TABLET;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr	CAHN
		107MG	A076635	002	Oct 31, 2005	Apr	CAHN
AB		160MG	A076635	003	Oct 31, 2005	Apr	CAHN

FENOFIBRIC ACIDTABLET;ORAL
FIBRICOR

	TRIBUTE PHARMS INTL	35MG
+		105MG

N022418	001	Aug 14, 2009	Jun	CAHN
N022418	002	Aug 14, 2009	Jun	CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
----	---------------------	-----------	---------	-----	--------------	-----	------

FENTANYL-12

AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun	NEWA
----	------------------	------------	---------	-----	--------------	-----	------

FENTANYL-25

AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
----	---------------------	----------	---------	-----	--------------	-----	------

FENTANYL-50

AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
----	---------------------	----------	---------	-----	--------------	-----	------

FENTANYL-75

AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN
----	---------------------	----------	---------	-----	--------------	-----	------

FENTANYL CITRATEFILM;BUCCAL
ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE
@		EQ 0.4MG BASE
@		EQ 0.6MG BASE
@		EQ 0.8MG BASE
@		EQ 1.2MG BASE

N022266	001	Jul 16, 2009	Mar	CAHN
N022266	002	Jul 16, 2009	Mar	CAHN
N022266	003	Jul 16, 2009	Mar	CAHN
N022266	004	Jul 16, 2009	Mar	CAHN
N022266	005	Jul 16, 2009	Mar	CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN
----	---	--------------------	-------------------	---------	-----	--------------	-----	------

FENTANYL HYDROCHLORIDESYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

@ THE MEDICINES CO

		10.8MCG
+		EQ 40MCG BASE/ACTIVATION

N021338	001	May 22, 2006	Apr	CAHN
N021338	001	May 22, 2006	Jun	CMFD

FERRIC CITRATETABLET;ORAL
AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON
---	-----------------	---------------

N205874	001	Sep 05, 2014	Jan	CTNA
---------	-----	--------------	-----	------

FERRIC PYROPHOSPHATE CITRATESOLUTION;IV (INFUSION)
TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)
---	----------------------	----------------------------------

N206317	001	Jan 23, 2015	Jan	NEWA
---------	-----	--------------	-----	------

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun	NEWA
AB		100MG	A202821	002	Jul 08, 2015	Jun	NEWA
AB		150MG	A202821	003	Jul 08, 2015	Jun	NEWA
AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN

TABLET; ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
AB		100MG	A078423	002	Mar 07, 2011	May CMFD
AB		150MG	A078423	003	Mar 07, 2011	May CMFD
AB		200MG	A078423	004	Mar 07, 2011	May CMFD

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr NEWA
>A> AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

	@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr CAHN
AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun NEWA
----	----------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

GEL; TOPICAL

FLUOCINONIDE

AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr CAHN
----	------------------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM; TOPICAL

CARAC

AB	+ VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr CFTG
	+	0.5%	N020985	001	Oct 27, 2000	Feb CAHN

FLUOROURACIL

AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr NEWA
----	------------------	------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar DISC
	+ MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CTEC
	@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr CAHN

FLURANDRENOLIDEOINTMENT; TOPICAL
CORDRAN+ AQUA PHARMS 0.05%
0.05%N012806 001
N012806 001Jun CRLD
May CMFDTAPE; TOPICAL
CORDRAN

+ ACTAVIS LABS UT INC 0.004MG/SQ CM

N016455 001

Mar CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATEPOWDER; INHALATION
BREO ELLIPTA

GLAXO GRP LTD 0.2MG/INH; EQ 0.025MG BASE/INH

N204275 002 Apr 30, 2015 Apr NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

>A> AB ANI PHARMS INC 25MG
 >A> @ 25MG
 >A> AB 50MG
 >A> @ 50MG
 >A> AB 100MG
 >A> @ 100MG
 >D> AB BARR 25MG
 >D> AB 50MG
 >D> AB 100MG
 >D> @ IVAX SUB TEVA PHARMS 25MG
 >D> @ 50MG
 >D> @ 100MG

A075897 001 Jan 25, 2001 Jul CAHN
 A075898 001 Mar 12, 2001 Jul CAHN
 A075897 002 Jan 25, 2001 Jul CAHN
 A075898 002 Mar 12, 2001 Jul CAHN
 A075897 003 Jan 25, 2001 Jul CAHN
 A075898 003 Mar 12, 2001 Jul CAHN
 A075897 001 Jan 25, 2001 Jul CAHN
 A075897 002 Jan 25, 2001 Jul CAHN
 A075897 003 Jan 25, 2001 Jul CAHN
 A075898 001 Mar 12, 2001 Jul CAHN
 A075898 002 Mar 12, 2001 Jul CAHN
 A075898 003 Mar 12, 2001 Jul CAHN

FOLIC ACIDTABLET; ORAL
FOLIC ACID

>A> AA NUVO PHARM INC 1MG

A204418 001 Jul 28, 2015 Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD 10MG; 12.5MG
 AB 20MG; 12.5MG

A076739 001 Dec 17, 2004 Apr CAHN
 A076739 002 Dec 17, 2004 Apr CAHN

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

@ IGI LABS INC 10MG/ML
 @ 10MG/ML

A070095 001 Sep 09, 1985 Mar CAHN
 A070096 001 Sep 09, 1985 Mar CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB SUN PHARM INDS LTD 100MG
 AB 300MG
 AB 400MG

A076606 001 Oct 07, 2005 Apr CAHN
 A076606 002 Oct 07, 2005 Apr CAHN
 A076606 003 Oct 07, 2005 Apr CAHN

TABLET; ORAL
GABAPENTIN

@ HIKMA PHARMS 600MG
 @ 800MG

A078782 001 Jul 21, 2011 Jun DISC
 A078782 002 Jul 21, 2011 Jun DISC

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+ LIEBEL-FLARSHEIM 1654.5MG/5ML (330.9MG/ML)
 + 3309MG/10ML (330.9MG/ML)
 + 4963.5MG/15ML (330.9MG/ML)
 + 6618MG/20ML (330.9MG/ML)
 + 16.545GM/50ML (330.9MG/ML)

N020937 001 Dec 08, 1999 Feb CAHN
 N020937 002 Dec 08, 1999 Feb CAHN
 N020937 003 Dec 08, 1999 Feb CAHN
 N020937 004 Dec 08, 1999 Feb CAHN
 N020975 001 Dec 08, 1999 Feb CAHN

OPTIMARK IN PLASTIC CONTAINER

+ LIEBEL-FLARSHEIM 3309MG/10ML (330.9MG/ML)
 + 4963.5MG/15ML (330.9MG/ML)
 + 6618MG/20ML (330.9MG/ML)
 + 9927MG/30ML (330.9MG/ML)

N020976 002 Dec 08, 1999 Feb CAHN
 N020976 003 Dec 08, 1999 Feb CAHN
 N020976 004 Dec 08, 1999 Feb CAHN
 N020976 001 Dec 08, 1999 Feb CAHN

>A>	<u>GEFITINIB</u>				
>A>	TABLET; ORAL				
>A>	IRESSA				
>A>	+	ASTRAZENECA PHARMS	250MG	N206995 001	Jul 13, 2015 Jul NEWA
	<u>GEMIFLOXACIN MESYLATE</u>				
	TABLET; ORAL				
	FACTIVE				
AB	+	LG LIFE SCIENCES	EQ 320MG BASE	N021158 001	Apr 04, 2003 Jun CFTG
		GEMIFLOXACIN MESYLATE			
AB		ORCHID HLTHCARE	EQ 320MG BASE	A090466 001	Jun 15, 2015 Jun NEWA
	<u>GLATIRAMER ACETATE</u>				
	INJECTABLE; SUBCUTANEOUS				
	COPAXONE				
AP	+	TEVA PHARMS USA	20MG/ML	N020622 002	Feb 12, 2002 Mar CFTG
		GLATOPA			
AP		SANDOZ INC	20MG/ML	A090218 001	Apr 16, 2015 Mar NEWA
	<u>GLIMEPIRIDE</u>				
	TABLET; ORAL				
	GLIMEPIRIDE				
	@	HIKMA PHARMS	1MG	A078952 001	Aug 01, 2013 Apr DISC
	@		2MG	A078952 002	Aug 01, 2013 Apr DISC
	@		4MG	A078952 003	Aug 01, 2013 Apr DISC
	<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE</u>				
	TABLET; ORAL				
	AVANDARYL				
	@	SB PHARMCO	1MG; 4MG	N021700 001	Nov 23, 2005 Jun DISC
	@		2MG; 4MG	N021700 002	Nov 23, 2005 Jun DISC
	@		2MG; 8MG	N021700 004	Mar 30, 2007 Jun DISC
	@		4MG; 4MG	N021700 003	Nov 23, 2005 Jun DISC
	@		4MG; 8MG	N021700 005	Mar 30, 2007 Jun DISC
	<u>GLIPIZIDE</u>				
	TABLET, EXTENDED RELEASE; ORAL				
	GLIPIZIDE				
AB		MYLAN PHARMS INC	2.5MG	A202298 001	May 19, 2015 May NEWA
AB			5MG	A202298 002	May 19, 2015 May NEWA
AB			10MG	A202298 003	May 19, 2015 May NEWA
	<u>GLUCAGON HYDROCHLORIDE</u>				
	POWDER; INTRAMUSCULAR, INTRAVENOUS				
	GLUCAGON				
	+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849 001	May 08, 2015 May NEWA
	<u>GLYCEROL PHENYLBUTYRATE</u>				
	LIQUID; ORAL				
	RAVICTI				
	+	HORIZON THERAPS INC	1.1GM/ML	N203284 001	Feb 01, 2013 May CAHN
	<u>GLYCOPYRROLATE</u>				
	INJECTABLE; INJECTION				
	ROBINUL				
AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558 001	Jun CAHN
	TABLET; ORAL				
	GLYCOPYRROLATE				
AA		SUN PHARM INDS LTD	1MG	A040844 001	Aug 18, 2009 Apr CAHN
AA			2MG	A040844 002	Aug 18, 2009 Apr CAHN
	<u>GRANISETRON HYDROCHLORIDE</u>				
	INJECTABLE; INJECTION				
	GRANISETRON HYDROCHLORIDE				
AP		BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863 001	Jun 30, 2008 Jan CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880 001	Jun 30, 2008 Jan CAHN
	@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008 Apr CAHN
	@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008 Apr CAHN
AP		EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177 001	Dec 31, 2007 Jun CAHN

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
FLOWTUSS

	MIKART INC	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	May NEWA
--	------------	---------------------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYCOFENIX

+	MIKART INC	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	May NEWA
---	------------	------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
AB	SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
AB		EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
AB		EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
AB		EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
AB	TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
AB	TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
@		1MG	A071129	001	Feb 17, 1987	Jun CAHN
@		5MG	A071131	001	Feb 17, 1987	Jun CAHN
@		10MG	A071132	001	May 12, 1987	Jun CAHN
@		20MG	A071133	001	May 12, 1987	May CAHN
@	ROXANE	2MG	A071130	001	Feb 17, 1987	Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL INTENSOL

@	CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May CAHN
---	------------------	----------------	---------	-----	--------------	----------

INJECTABLE;INJECTION
HALOPERIDOL

@	CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr CAHN
@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

AP	+	EUROHLTH INTL SARL	1,000 UNITS/ML	N017037	001		Jun CAHN
AP	+		5,000 UNITS/ML	N017037	002		Jun CAHN
		@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun CAHN
AP	+		10,000 UNITS/ML	N017037	003		Jun CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb CRLD
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun NEWA

HYDROCHLOROTHIAZIDECAPSULE; ORAL
MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb CAHN
----	---	---------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG; 10MG	A076007	001	Jul 01, 2002	Apr CAHN
AB			12.5MG; 20MG	A076007	002	Jul 01, 2002	Apr CAHN
AB			25MG; 20MG	A076007	003	Jul 01, 2002	Apr CAHN
ZESTORETIC							
AB		ALVOGEN IPCO SARL	12.5MG; 10MG	N019888	003	Nov 18, 1993	Feb CAHN
AB	+		12.5MG; 20MG	N019888	001	Sep 20, 1990	Feb CAHN
AB	+		25MG; 20MG	N019888	002	Jul 20, 1989	Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATETABLET, EXTENDED RELEASE; ORAL
DUTOPROL

		CONCORDIA PHARMS INC	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun CAHN
			12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun CAHN
	+		12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	@	ANI PHARMS INC	25MG; 40MG	A070704	001	Oct 01, 1986	Jul CAHN
>A>	@		25MG; 80MG	A070705	001	Oct 01, 1986	Jul CAHN
>D>	@	BARR	25MG; 40MG	A070704	001	Oct 01, 1986	Jul CAHN
>D>	@		25MG; 80MG	A070705	001	Oct 01, 1986	Jul CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	12.5MG; EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr CAHN
AB			12.5MG; EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr CAHN
AB			25MG; EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr CAHN

HYDROCODONE BITARTRATECAPSULE, EXTENDED RELEASE; ORAL
ZOHYDRO ER

+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr CAHN
		15MG	N202880	002	Oct 25, 2013	Apr CAHN
		20MG	N202880	003	Oct 25, 2013	Apr CAHN
		30MG	N202880	004	Oct 25, 2013	Apr CAHN
		40MG	N202880	005	Oct 25, 2013	Apr CAHN
		50MG	N202880	006	Oct 25, 2013	Apr CAHN
+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun CAHN
		15MG	N202880	002	Oct 25, 2013	Jun CAHN
		20MG	N202880	003	Oct 25, 2013	Jun CAHN
		30MG	N202880	004	Oct 25, 2013	Jun CAHN
		40MG	N202880	005	Oct 25, 2013	Jun CAHN
		50MG	N202880	006	Oct 25, 2013	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL
HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar CRLD
---	------------------	------	---------	-----	--------------	----------

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT		RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar CAHN
----	--	-------------------	------	---------	-----	--------------	----------

POWDER; FOR RX COMPOUNDING
HYDRO-RX

	@	X GEN PHARMS	100%	A085982	001		Apr DISC
--	---	--------------	------	---------	-----	--	----------

TABLET; ORAL

HYDROCORTISONE

AB		HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb NEWA
AB			10MG	A083365	003	Feb 23, 2015	Feb NEWA
AB			20MG	A083365	001		Feb CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

@ X GEN PHARMS

100%

A085981 001

Apr DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

@ G AND W LABS INC

0.2%

A074489 001 Aug 12, 1998

Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

CORTISPORIN

AT + CITRON PHARMA LLC

1%;EQ 3.5MG BASE/ML;10,000
UNITS/ML

N060613 001

Jun CMS2

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB PADDOCK LLC

8MG

A204278 001 Apr 06, 2015

Mar NEWA

AB

12MG

A204278 002 Apr 06, 2015

Mar NEWA

AB

16MG

A204278 003 Apr 06, 2015

Mar NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

@ SERB SAS

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

Apr CAHN

+

5GM/VIAL (5GM/KIT)

N022041 001 Apr 08, 2011

Apr CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

PLAQUENIL

AB + CONCORDIA PHARMS INC

200MG

N009768 001

Jun CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

HYDROXYPROGESTERONE CAPROATE

@ ACTAVIS LABS UT INC

125MG/ML

N017439 001

Mar CAHN

@

250MG/ML

N017439 002

Mar CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB ELITE LABS INC

10MG

A040600 001 Dec 28, 2004

Jun CAHN

AB

25MG

A040602 001 Dec 28, 2004

Jun CAHN

AB

50MG

A040604 001 Dec 28, 2004

Jun CAHN

AB HERITAGE PHARMA

10MG

A204279 001 Aug 20, 2014

Mar CAHN

AB

25MG

A204279 002 Aug 20, 2014

Mar CAHN

AB

50MG

A204279 003 Aug 20, 2014

Mar CAHN

AB MIKAH PHARMA

10MG

A040600 001 Dec 28, 2004

Mar CMFD

AB

25MG

A040602 001 Dec 28, 2004

Mar CMFD

AB

50MG

A040604 001 Dec 28, 2004

Mar CMFD

>D> AB MUTUAL PHARM

10MG

A089381 001 May 19, 1986

Jul DISC

>A> @

10MG

A089381 001 May 19, 1986

Jul DISC

>D> AB

25MG

A089382 001 May 19, 1986

Jul DISC

>A> @

25MG

A089382 001 May 19, 1986

Jul DISC

>D> AB

50MG

A089383 001 May 19, 1986

Jul DISC

>A> @

50MG

A089383 001 May 19, 1986

Jul DISC

>D> AB WATSON LABS

10MG

A088348 001 Sep 15, 1983

Jul DISC

>A> @

10MG

A088348 001 Sep 15, 1983

Jul DISC

>D> AB

25MG

A088349 001 Sep 15, 1983

Jul DISC

>A> @

25MG

A088349 001 Sep 15, 1983

Jul DISC

>D> AB

50MG

A088350 001 Sep 15, 1983

Jul DISC

>A> @

50MG

A088350 001 Sep 15, 1983

Jul DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB HERITAGE PHARMA

EQ 25MG HYDROCHLORIDE

A201507 001 Jun 03, 2013

Mar CAHN

AB

EQ 50MG HYDROCHLORIDE

A201507 002 Jun 03, 2013

Mar CAHN

IBUPROFENTABLET; ORAL
IBUPROFEN

>D>	AB	VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul	DISC
>A>		@	300MG	A071230	001	Oct 22, 1986	Jul	DISC
>D>	AB		400MG	A071231	001	Oct 22, 1986	Jul	DISC
>A>		@	400MG	A071231	001	Oct 22, 1986	Jul	DISC
>D>	AB		600MG	A071232	001	Oct 22, 1986	Jul	DISC
>A>		@	600MG	A071232	001	Oct 22, 1986	Jul	DISC
>D>	AB		800MG	A072004	001	Nov 18, 1987	Jul	DISC
>A>		@	800MG	A072004	001	Nov 18, 1987	Jul	DISC

ILOPERIDONETABLET; ORAL
FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan	CAHN
		2MG	N022192	002	May 06, 2009	Jan	CAHN
		4MG	N022192	003	May 06, 2009	Jan	CAHN
		6MG	N022192	004	May 06, 2009	Jan	CAHN
		8MG	N022192	005	May 06, 2009	Jan	CAHN
		10MG	N022192	006	May 06, 2009	Jan	CAHN
		12MG	N022192	007	May 06, 2009	Jan	CAHN

IMIQUIMODCREAM; TOPICAL
IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr	CAHN
----	------------------	----	---------	-----	--------------	-----	------

INDAPAMIDETABLET; ORAL
INDAPAMIDE

>A>	AB	ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul	CAHN
>A>		@	1.25MG	A074498	002	Feb 12, 1998	Jul	CAHN
>A>	AB		2.5MG	A074299	001	Jul 27, 1995	Jul	CAHN
>A>		@	2.5MG	A074498	001	Oct 31, 1996	Jul	CAHN
>D>	AB	IVAX SUB TEVA PHARMS	1.25MG	A074299	002	Apr 29, 1996	Jul	CAHN
>D>	AB		2.5MG	A074299	001	Jul 27, 1995	Jul	CAHN
>D>		@ TEVA	1.25MG	A074498	002	Feb 12, 1998	Jul	CAHN
>D>		@	2.5MG	A074498	001	Oct 31, 1996	Jul	CAHN

INGENOL MEBUTATEGEL; TOPICAL
PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May	CRLD
---	---------------	--------	---------	-----	--------------	-----	------

INSULIN GLARGINE RECOMBINANTSOLUTION; SUBCUTANEOUS
TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Feb	NEWA
---	--------------------	-----------------------------	---------	-----	--------------	-----	------

INSULIN LISPRO RECOMBINANTSOLUTION; SUBCUTANEOUS
HUMALOG KWIKPEN

+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May	NEWA
---	------------------	--------------	---------	-----	--------------	-----	------

INSULIN RECOMBINANT HUMANPOWDER; INHALATION
AFREZZA

	SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr	NEWA
--	----------------	--------------	---------	-----	--------------	-----	------

IOHEXOLFOR SOLUTION; ORAL
ORALTAG

	INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar	NEWA
--	----------------------	-----------	---------	-----	--------------	-----	------

IOPAMIDOLINJECTABLE; INJECTION
IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan	DISC
---	--------------------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300

@	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan	DISC
---	--------------------	-----	---------	-----	--------------	-----	------

INJECTABLE; INJECTION							
IOPAMIDOL-370							
@	FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan	DISC
ISOVUE-200							
+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb	CTEC
ISOVUE-250							
+	BRACCO	51%	N018735	007	Jul 06, 1992	Feb	CTEC
+		51%	N020327	002	Oct 12, 1994	Feb	CTEC
ISOVUE-300							
+	BRACCO	61%	N020327	003	Oct 12, 1994	Feb	CTEC
ISOVUE-370							
+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb	CTEC
<u>IOTHALAMATE MEGLUMINE</u>							
INJECTABLE; INJECTION							
CONRAY							
+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb	CAHN
CONRAY 30							
+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb	CAHN
CONRAY 43							
+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb	CAHN
SOLUTION; INTRAVESICAL							
CYSTO-CONRAY II							
	LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb	CAHN
<u>IOVERSOL</u>							
INJECTABLE; INJECTION							
OPTIRAY 160							
@	LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb	CAHN
OPTIRAY 240							
+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb	CAHN
@		51%	N020923	001	May 28, 1998	Feb	CAHN
OPTIRAY 300							
+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb	CAHN
+		64%	N020923	004	May 13, 1999	Feb	CAHN
OPTIRAY 320							
+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb	CAHN
@		68%	N020923	002	May 29, 1998	Feb	CAHN
OPTIRAY 350							
+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb	CAHN
+		74%	N020923	003	May 28, 1998	Feb	CAHN
<u>IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM</u>							
INJECTABLE; INJECTION							
HEXABRIX							
@	GUERBET	39.3%; 19.6%	N018905	002	Jul 26, 1985	May	DISC
<u>IRBESARTAN</u>							
TABLET; ORAL							
IRBESARTAN							
AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb	NEWA
AB		150MG	A203534	002	Feb 23, 2015	Feb	NEWA
AB		300MG	A203534	003	Feb 23, 2015	Feb	NEWA
<u>IRON DEXTRAN</u>							
INJECTABLE; INJECTION							
INFED							
BP	+ ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar	CAHN
<u>ISAVUCONAZONIUM SULFATE</u>							
CAPSULE; ORAL							
CRESEMBA							
+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar	NEWA
POWDER; IV (INFUSION)							
CRESEMBA							
+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar	NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
+		40MG	N012093	001	Jul 29, 1988	Feb CAHN

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

RANBAXY

25MG

N021951 005 Aug 15, 2014 Feb NEWA

35MG

N021951 006 Aug 15, 2014 Feb NEWA

SOTRET

AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
AB		20MG	A076041	002	Dec 24, 2002	Apr CAHN
AB		30MG	A076503	001	Jun 20, 2003	Apr CAHN
AB		40MG	A076041	003	Dec 24, 2002	Apr CAHN

ZENATANE

AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA
----	--------------------	------	---------	-----	--------------	----------

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
AB		5MG	A077169	002	Apr 24, 2006	Mar CAHN

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

AMGEN INC

EQ 5MG BASE

N206143 001 Apr 15, 2015 Apr NEWA

+

EQ 7.5MG BASE

N206143 002 Apr 15, 2015 Apr NEWA

IVACAFTOR

GRANULE; ORAL

KALYDECO

VERTEX PHARMS INC

50MG/PACKET

N207925 001 Mar 17, 2015 Mar NEWA

+

75MG/PACKET

N207925 002 Mar 17, 2015 Mar NEWA

IVACAFTOR; LUMACAFTOR

TABLET; ORAL

ORKAMBI

>A>	+	VERTEX PHARMS INC	125MG;200MG	N206038	001	Jul 02, 2015	Jul NEWA
-----	---	-------------------	-------------	---------	-----	--------------	----------

IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+ R-PHARM US LLC 15MG/VIAL

N022065 001 Oct 16, 2007 Jun CAHN

+ 45MG/VIAL

N022065 002 Oct 16, 2007 Jun CAHN

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN

@ EUROHLTH INTL SARL

EQ 75MG BASE/2ML

A062324 001 Jun CAHN

@

EQ 500MG BASE/2ML

A062324 002 Jun CAHN

@

EQ 1GM BASE/3ML

A062324 003 Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

@ CLARIS PHARMASERVICE

15MG/ML

A075631 002 Jun 29, 2001 Apr CAHN

@

30MG/ML

A075631 001 Jun 29, 2001 Apr CAHN

@ EUROHLTH INTL SARL

15MG/ML

A075772 001 Jul 21, 2004 Jun CAHN

@

30MG/ML

A075772 002 Jul 21, 2004 Jun CAHN

SPRAY, METERED; NASAL

SPRIX

+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan CAHN
---	---------------	---------------	---------	-----	--------------	----------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDESOLUTION; IRRIGATION
OMIDRIA

+	OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb CPOT
---	--------	--------------------------------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

@ CLARIS PHARMASERVICE 5MG/ML

A076051 001 Jul 05, 2002 Apr CAHN

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan CMFD

LACTULOSE

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

+	MERCK SHARP DOHME	150MG; EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb NEWA
---	-------------------	----------------------	---------	-----	--------------	----------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	STRIDES ARCOLAB LTD	150MG; 300MG	A079128	001	May 13, 2015	Apr NEWA
----	---------------------	--------------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@	HIKMA PHARMS	25MG
@		100MG
@		150MG
@		200MG

A078134	001	Apr 19, 2011	May DISC
A078134	002	Apr 19, 2011	May DISC
A078134	003	Apr 19, 2011	May DISC
A078134	004	Apr 19, 2011	May DISC

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar CAHN
---	----------------------	---------------	---------	-----	--------------	----------

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

EISAI INC EQ 4MG BASE

N206947 001 Feb 13, 2015 Feb NEWA

+ EQ 10MG BASE

N206947 002 Feb 13, 2015 Feb NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

>A>	AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul NEWA
-----	----	--------------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May NEWA
----	-------------	----------	---------	-----	--------------	----------

TABLET; ORAL

SPRITAM

>A>		APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul NEWA
>A>			500MG	N207958	002	Jul 31, 2015	Jul NEWA
>A>			750MG	N207958	003	Jul 31, 2015	Jul NEWA
>A>			1GM	N207958	004	Jul 31, 2015	Jul NEWA

TABLET, EXTENDED RELEASE; ORAL

ELEPSIA XR

SPARC 1GM
1.5GM

N204417	001	Mar 02, 2015	Mar NEWA
N204417	002	Mar 02, 2015	Mar NEWA

LEVETIRACETAM

APOTEX INC 1GM

A202958 001 Feb 25, 2015 Feb NEWA

AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May NEWA
----	--------------	-------	---------	-----	--------------	----------

AB		750MG	A203468	002	May 21, 2015	May NEWA
----	--	-------	---------	-----	--------------	----------

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

@ TEVA PHARMS USA 200MG/ML

A075881 001 Mar 29, 2001 Apr DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB APOTEX INC 5MG

A203027 001 Feb 13, 2015 Feb NEWA

AB SUN PHARM INDS LTD 5MG

A201653 001 Jun 26, 2015 Jun NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP CLARIS PHARMASERVICE EQ 500MG/20ML (EQ 25MG/ML)

A091436 001 Jun 05, 2013 Apr CAHN

>A> AP HOSPIRA INC EQ 500MG/20ML (EQ 25MG/ML)

A078577 001 Aug 12, 2015 Jul NEWA

>A> AP EQ 750MG/30ML (EQ 25MG/ML)

A078577 002 Aug 12, 2015 Jul NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS PHARMASERVICE EQ 250MG/50ML (EQ 5MG/ML)

A091397 001 Aug 08, 2013 Apr CAHN

AP EQ 500MG/100ML (EQ 5MG/ML)

A091397 002 Aug 08, 2013 Apr CAHN

AP EQ 750MG/150ML (EQ 5MG/ML)

A091397 003 Aug 08, 2013 Apr CAHN

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

>D> AT NEXUS PHARMS 0.5%

A077700 001 Dec 20, 2010 Jul CRLD

>A> AT + 0.5%

A077700 001 Dec 20, 2010 Jul CRLD

>D> QUIXIN

>D> AT + SANTEN 0.5%

N021199 001 Aug 18, 2000 Jul DISC

>A> @ 0.5%

N021199 001 Aug 18, 2000 Jul DISC

TABLET; ORAL

LEVOFLOXACIN

AB JUBILANT GENERICS 250MG

A203613 001 Jun 19, 2015 Jun NEWA

AB 500MG

A203613 002 Jun 19, 2015 Jun NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

SANDOZ EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

A203563 002 Mar 09, 2015 Feb NEWA

SANDOZ INC EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

A203563 001 Mar 09, 2015 Feb NEWA

+ EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

A203563 002 Mar 09, 2015 Mar CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

LILETTA

MEDICINES360 52MG

N206229 001 Feb 26, 2015 Feb NEWA

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

+ SENTYNL THERAPS INC 2MG

A074278 001 Mar 31, 2000 Apr CAHN

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

>A> AT AMNEAL PHARMS 5%

A206297 001 Aug 07, 2015 Jul NEWA

PATCH; TOPICAL

LIDOCAINE

AB ACTAVIS LABS UT INC 5%

A200675 001 Aug 23, 2012 Mar CAHN

>A> AB MYLAN TECHNOLOGIES 5%

A202346 001 Aug 07, 2015 Jul NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@ EUROHLTH INTL SARL 1%

A080407 001 Mar CAHN

@ 2%

A080407 002 Mar CAHN

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ EUROHLTH INTL SARL 1%

A084625 001 Feb CAHN

@ 2%

A084625 002 Feb CAHN

JELLY; TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%

A080429 001

Jan CAHN

LIDOCAINE HYDROCHLORIDE

@ G AND W LABS INC 2%

A081318 001 Apr 29, 1993

Apr CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ACTAVIS LABS UT INC 2.5%; 2.5%

N019941 001 Dec 30, 1992

Feb CAHN

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC

145MCG

N202811 001 Aug 30, 2012

Mar CAHN

+

290MCG

N202811 002 Aug 30, 2012

Mar CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

AP + PHARMACIA AND UPJOHN EQ 300MG BASE/ML

N050317 001

May CFTG

LINCOMYCIN

AP X-GEN PHARMS INC EQ 300MG BASE/ML

A201746 001 Jun 04, 2015

May NEWA

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

AB ROXANE 100MG/5ML

A200068 001 Jun 03, 2015

May NEWA

ZYVOX

AB + PHARMACIA AND UPJOHN 100MG/5ML

N021132 001 Apr 18, 2000

May CFTG

SOLUTION; IV (INFUSION)

LINEZOLID

AP HOSPIRA INC 600MG/300ML (2MG/ML)

A205442 001 Jul 07, 2015

Jun NEWA

>A> AP SANDOZ INC 200MG/100ML (2MG/ML)

A200904 001 Jul 16, 2015

Jul NEWA

>A> AP 600MG/300ML (2MG/ML)

A200904 002 Jul 16, 2015

Jul NEWA

AP TEVA PHARMS 600MG/300ML (2MG/ML)

A200222 001 Jun 27, 2012

May CDFR

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA INC 600MG/300ML (2MG/ML)

N206473 001 Jun 18, 2015

Jun NEWA

ZYVOX

>D> PHARMACIA AND UPJOHN 200MG/100ML (2MG/ML)

N021131 001 Apr 18, 2000

Jul CTEC

>A> AP 200MG/100ML (2MG/ML)

N021131 001 Apr 18, 2000

Jul CTEC

200MG/100ML (2MG/ML)

N021131 001 Apr 18, 2000

May CDFR

400MG/200ML (2MG/ML)

N021131 002 Apr 18, 2000

May NEWA

AP + 600MG/300ML (2MG/ML)

N021131 003 Apr 18, 2000

May NEWA

TABLET; ORAL

LINEZOLID

AB TEVA PHARMS USA 600MG

A078061 001 May 18, 2015

May NEWA

ZYVOX

AB + PHARMACIA AND UPJOHN 600MG

N021130 002 Apr 18, 2000

May CFTG

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB SUN PHARM INDS LTD 2.5MG

A075944 001 Jul 01, 2002

Apr CAHN

AB 5MG

A075944 002 Jul 01, 2002

Apr CAHN

AB 10MG

A075944 003 Jul 01, 2002

Apr CAHN

AB 20MG

A075944 004 Jul 01, 2002

Apr CAHN

AB 30MG

A075944 006 Feb 11, 2003

Apr CAHN

AB 40MG

A075944 005 Jul 01, 2002

Apr CAHN

ZESTRIL

AB ALVOGEN IPCO SARL 2.5MG

N019777 005 Apr 29, 1993

Feb CAHN

AB 5MG

N019777 001 May 19, 1988

Feb CAHN

AB 10MG

N019777 002 May 19, 1988

Feb CAHN

AB 20MG

N019777 003 May 19, 1988

Feb CAHN

AB 30MG

N019777 006 Jan 20, 1999

Feb CAHN

AB + 40MG

N019777 004 May 19, 1988

Feb CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May NEWA
	@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb DISC
>A> AB	UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015	Jul NEWA

LOMITAPIDE MESYLATE

CAPSULE;ORAL
JUXTAPID

	AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr NEWA
		EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr NEWA
		EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr NEWA

LOMUSTINE

CAPSULE;ORAL
GLEOSTINE

	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan NEWA
--	---------------	-----	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
IMODIUM

>A>	@ J AND J CONSUMER INC	2MG	N017690	001		Jul CAHN
>A> AB	+	2MG	N017694	001		Jul CAHN
>D> AB	+	MCNEIL CONS	N017694	001		Jul CAHN
>D>	@ MCNEIL PED	2MG	N017690	001		Jul CAHN

LOPINAVIR; RITONAVIR

CAPSULE;ORAL
KALETRA

	@ ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000	Jun DISC
--	----------	----------------	---------	-----	--------------	----------

LORAZEPAM

INJECTABLE;INJECTION
ATIVAN

AP	+	EUROHLTH INTL SARL	2MG/ML	N018140	001	Jun CAHN
AP	+		4MG/ML	N018140	002	Jun CAHN

TABLET;ORAL
LORAZEPAM

AB	SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Apr CAHN
AB		1MG	A076045	002	Aug 29, 2001	Apr CAHN
AB		2MG	A076045	003	Aug 29, 2001	Apr CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

>A> AB	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul NEWA
>A> AB		50MG	A203835	002	Aug 12, 2015	Jul NEWA
>A> AB		100MG	A203835	003	Aug 12, 2015	Jul NEWA
AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb CMFD
AB		50MG	A091129	002	Oct 06, 2010	Feb CMFD
AB		100MG	A091129	003	Oct 06, 2010	Feb CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL
ALTOPREV

	@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May CAHN
		20MG	N021316	002	Jun 26, 2002	May CAHN
		40MG	N021316	003	Jun 26, 2002	May CAHN
+		60MG	N021316	004	Jun 26, 2002	May CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL
LOXITANE C

	@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar CAHN
--	-----------------------	-----------------	---------	-----	--	----------

INJECTABLE;INJECTION

LOXITANE IM

	@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar CAHN
--	-----------------------	-----------------	---------	-----	--	----------

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CAHN
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CAHN
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CAHN
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CAHN

LOXITANE

@ ACTAVIS LABS UT INC

@

@

@

TABLET;ORAL

LOXITANE

@ ACTAVIS LABS UT INC

@

@

LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

@ DISCOVERY LABS

8.5ML

N021746 001 Mar 06, 2012 May DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

32MG/100ML;128MG/100ML;234MG/100ML

N019047 001 Jun 15, 1984 Mar DISC

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr CDFR
AP	+ FRESenius KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+ FRESenius KABI USA 1GM/2ML (500MG/ML)

N019316 002 Sep 08, 1986 Apr NEWA

MANNITOL

INJECTABLE;INJECTION

MANNITOL 25%

@ IGI LABS INC

@

12.5GM/50ML

12.5GM/50ML

A089239 001 May 06, 1987 Mar CAHN

A089240 001 May 06, 1987 Mar CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@ VINTAGE PHARMS

@

12.5MG

25MG

A040179 001 Jan 30, 1997 Jun DISC

A040179 002 Jan 30, 1997 Jun DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMENDA XR

FOREST LABS LLC

7MG

14MG

21MG

+

28MG

N022525 001 Jun 21, 2010 Mar CAHN

N022525 002 Jun 21, 2010 Mar CAHN

N022525 003 Jun 21, 2010 Mar CAHN

N022525 004 Jun 21, 2010 Mar CAHN

SOLUTION;ORAL

NAMENDA

+ FOREST LABS LLC

2MG/ML

N021627 001 Apr 18, 2005 Mar CAHN

TABLET;ORAL

MEMANTINE

SUN PHARMA GLOBAL

5MG

10MG

A090058 001 May 05, 2010 Mar CMFD

A090058 002 May 05, 2010 Mar CMFD

MEMANTINE HYDROCHLORIDE

AMNEAL PHARMS

5MG

10MG

A090041 001 Apr 10, 2015 Mar NEWA

A090041 002 Apr 10, 2015 Mar NEWA

DR REDDYS LABS LTD

5MG

A090048 001 Apr 14, 2010 Jun CMFD

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		10MG	A090048	002	Apr 14, 2010	Jun	CMFD
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun	CMFD
	@	5MG	A079225	001	Jan 30, 2015	Mar	DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan	NEWA
AB		10MG	A079225	002	Jan 30, 2015	Jun	CMFD
	@	10MG	A079225	002	Jan 30, 2015	Mar	DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan	NEWA
AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May	CMFD
AB		10MG	A090052	002	Oct 25, 2011	May	CMFD
>A>	AB	5MG	A090043	001	Jul 31, 2015	Jul	NEWA
>A>	AB	10MG	A090043	002	Jul 31, 2015	Jul	NEWA
	NAMENDA						
AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Mar	CAHN

MENOTROPINS (FSH;LH)

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

@	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May	DISC
---	---------	-----------------------	---------	-----	--------------	-----	------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb	CAHN
AP		50MG/ML	A080445	002		Feb	CAHN
AP		75MG/ML	A080445	003		Feb	CAHN
AP		100MG/ML	A080445	004		Feb	CAHN
	@ IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May	CAHN
	@	50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN
	@	50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN
	@	50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN
	@	75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN
	@	100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

@	EUROHLTH INTL SARL	25MG/ML;25MG/ML	N011730	001		Jun	CAHN
---	--------------------	-----------------	---------	-----	--	-----	------

MEROPENEM

POWDER;IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B	BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr	NEWA
		1GM/VIAL	N202106	002	Apr 30, 2015	Apr	NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

APRISO

>D>	+	SALIX PHARMS	375MG	N022301	001	Oct 31, 2008	Jul	CAHN
>A>	+	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008	Jul	CAHN

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20

NORINYL

@	ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004		Mar	CAHN
---	---------------------	-----------	---------	-----	--	-----	------

TABLET;ORAL-21

NORINYL 1+50 21-DAY

@	ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002		Mar	CAHN
---	---------------------	------------	---------	-----	--	-----	------

TABLET;ORAL-28

NORINYL 1+50 28-DAY

+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Mar	CAHN
---	---------------------	------------	---------	-----	--	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@ MYLAN SPECILT 0.4%
 @ 0.6%
 @ WOCKHARDT 0.4%
 @ 0.6%

A071786 001 Aug 05, 1988 Apr DISC
 A070804 001 Aug 17, 1987 Apr DISC
 A075586 001 May 30, 2002 Apr DISC
 A075586 002 May 30, 2002 Apr DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@ G AND W LABS INC 10MG/5ML
 @ 10MG/5ML

A072761 001 Feb 27, 1992 Apr CAHN
 A073034 001 Aug 30, 1991 Apr CAHN

METAXALONE

TABLET; ORAL

METAXALONE

COREPHARMA 400MG
 640MG

A040486 001 Feb 27, 2015 Feb NEWA
 N022503 001 Jun 01, 2015 Jun NEWA

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ SUN PHARM INDS LTD 500MG/5ML

N021591 001 Sep 11, 2003 Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

AB NOVO NORDISK INC 500MG; 1MG
 AB + 500MG; 2MG

N022386 001 Jun 23, 2008 Jun CFTG
 N022386 002 Jun 23, 2008 Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB LUPIN LTD 500MG; 1MG
 AB 500MG; 2MG

A200624 001 Jul 15, 2015 Jun NEWA
 A200624 002 Jul 15, 2015 Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

@ SB PHARMC0 500MG; EQ 2MG BASE
 @ 500MG; EQ 4MG BASE
 @ 1GM; EQ 2MG BASE
 @ 1GM; EQ 4MG BASE

N021410 002 Oct 10, 2002 May DISC
 N021410 003 Oct 10, 2002 May DISC
 N021410 004 Aug 25, 2003 May DISC
 N021410 005 Aug 25, 2003 May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA 500MG; EQ 2MG BASE
 500MG; EQ 4MG BASE

A077337 001 May 07, 2014 May CTEC
 A077337 002 May 07, 2014 May CTEC

+ 1GM; EQ 4MG BASE
 1GM; EQ 2MG BASE

A077337 004 May 07, 2014 May CRLD
 A077337 003 May 07, 2014 May CTEC

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB HERITAGE PHARMA 5MG
 AB 10MG

A040734 001 Dec 14, 2007 Mar CAHN
 A040734 002 Dec 14, 2007 Mar CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

AP + EUROHLTH INTL SARL 1GM/10ML (100MG/ML)

N011790 001 Jun CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP FRESENIUS KABI USA EQ 25MG BASE/ML

A040265 001 Feb 26, 1999 May CMFD

TABLET; ORAL

METHOTREXATE SODIUM

AB ORION CORP ORION EQ 2.5MG BASE

A201749 001 May 21, 2015 May NEWA

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

AB ACTAVIS INC 10MG

A202603 001 Jun 09, 2015 May NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
APTENSIO XR							
	RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr	NEWA
		15MG	N205831	002	Apr 17, 2015	Apr	NEWA
		20MG	N205831	003	Apr 17, 2015	Apr	NEWA
		30MG	N205831	004	Apr 17, 2015	Apr	NEWA
		40MG	N205831	005	Apr 17, 2015	Apr	NEWA
		50MG	N205831	006	Apr 17, 2015	Apr	NEWA
	+	60MG	N205831	007	Apr 17, 2015	Apr	NEWA
RITALIN LA							
AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb	CRLD
	+	60MG	N021284	005	Oct 27, 2014	Feb	CRLD
TABLET, CHEWABLE;ORAL							
METHYLIN							
AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
AB		5MG	N021475	002	Apr 15, 2003	Feb	CFTG
AB	+	10MG	N021475	003	Apr 15, 2003	Feb	CFTG
METHYLPHENIDATE HYDROCHLORIDE							
AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
AB		5MG	A204115	002	Feb 25, 2015	Feb	NEWA
AB		10MG	A204115	003	Feb 25, 2015	Feb	NEWA
TABLET, EXTENDED RELEASE;ORAL							
METHYLIN ER							
AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May	CTEC
METHYLPHENIDATE HYDROCHLORIDE							
AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May	NEWA
AB		20MG	A207488	002	Jun 09, 2015	May	NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION							
METOPROLOL TARTRATE							
AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr	CAHN
TABLET;ORAL							
METOPROLOL TARTRATE							
	MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar	NEWA
		75MG	A076704	005	Mar 18, 2015	Mar	NEWA

METRONIDAZOLE

CREAM;TOPICAL							
NORITATE							
+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb	CAHN
GEL;VAGINAL							
METRONIDAZOLE							
+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CAHN
	NUVESSA						
+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CTNA
INJECTABLE;INJECTION							
METRONIDAZOLE IN PLASTIC CONTAINER							
AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr	CAHN
TABLET;ORAL							
METRONIDAZOLE							
AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May	NEWA
AB		500MG	A203974	002	May 29, 2015	May	NEWA

MICONAZOLE

TABLET;BUCCAL							
ORAVIG							
+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION							
MIDAZOLAM HYDROCHLORIDE							
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun	CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun	CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr	CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar	DISC
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar	DISC

INJECTABLE; INJECTION							
MIDAZOLAM HYDROCHLORIDE							
@	EQ 5MG BASE/ML	A078141	002	May 30,	2008	Mar	DISC
@	EQ 5MG BASE/ML	A078511	002	Nov 10,	2008	Mar	DISC
SYRUP; ORAL							
MIDAZOLAM HYDROCHLORIDE							
AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15,	2002	Apr CAHN
<u>MIGLITOL</u>							
TABLET; ORAL							
GLYSET							
AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18,	1996	Mar CTEC
AA		25MG	N020682	001	Dec 18,	1996	Feb CFTG
AB		50MG	N020682	002	Dec 18,	1996	Mar CTEC
AA		50MG	N020682	002	Dec 18,	1996	Feb CFTG
AB	+	100MG	N020682	003	Dec 18,	1996	Mar CTEC
AA	+	100MG	N020682	003	Dec 18,	1996	Feb CFTG
MIGLITOL							
AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24,	2015	Mar CTEC
AA		25MG	A203965	001	Feb 24,	2015	Feb NEWA
AB		50MG	A203965	002	Feb 24,	2015	Mar CTEC
AA		50MG	A203965	002	Feb 24,	2015	Feb NEWA
AB		100MG	A203965	003	Feb 24,	2015	Mar CTEC
AA		100MG	A203965	003	Feb 24,	2015	Feb NEWA
<u>MILRINONE LACTATE</u>							
INJECTABLE; INJECTION							
MILRINONE LACTATE							
AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28,	2002	Jan CRLD
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28,	2002	Jun CAHN
AP	+	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03,	2010 Jan CRLD
<u>MINOCYCLINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30,	2000	Apr CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30,	2000	Apr CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30,	2000	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30,	2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30,	2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30,	2000	Jun CAHN
CAPSULE, EXTENDED RELEASE; ORAL							
XIMINO							
@	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11,	2012	Apr CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11,	2012	Apr CAHN
@		EQ 90MG BASE	N201922	003	Jul 11,	2012	Apr CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11,	2012	Apr CAHN
@		EQ 135MG BASE	N201922	005	Jul 11,	2012	Apr CAHN
TABLET; ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06,	2004	Apr CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06,	2004	Apr CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06,	2004	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06,	2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06,	2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06,	2004	Jun CAHN
TABLET, EXTENDED RELEASE; ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25,	2014	Apr CAHN
AB		EQ 80MG BASE	A091118	004	Sep 25,	2014	Apr CAHN
AB		EQ 90MG BASE	A091118	005	Sep 25,	2014	Apr CAHN
AB		EQ 105MG BASE	A091118	006	Sep 25,	2014	Apr CAHN
AB		EQ 135MG BASE	A091118	008	Sep 25,	2014	Apr CAHN
<u>MIVACURIUM CHLORIDE</u>							
SOLUTION; INTRAVENOUS							
MIVACRON							
	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22,	1992	Jan NEWA
+		EO 20MG BASE/10ML (EO 2MG BASE/ML)	N020098	005	Jan 22,	1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

	COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
		10MG	A090453	002	Mar 20, 2015	Mar NEWA
+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

>A>	AB	AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA
-----	----	-------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

MONTELUKAST SODIUM

>A>	AB	AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
	AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

>A>	AB	AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA
>A>	AB		EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA
	AB	HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
	AB		EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
	AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
	AB	KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
	AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
	AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
AB1			40MG	N020616	009	Jul 09, 2012	May CTEC
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
AB1			70MG	N020616	010	Jul 09, 2012	May CTEC
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN
			130MG	N020616	011	Jul 09, 2012	Mar CAHN
			150MG	N020616	012	Jul 09, 2012	Mar CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	Mar CAHN

MORPHINE SULFATE

AB1		TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May NEWA
AB1			70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN
		INFUMORPH					
	+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN

MORPHINE SULFATE

AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG

SOLUTION; ORAL

MORPHINE SULFATE

AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
AA			100MG/5ML	A203518	002	May 12, 2015	May NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB		100MG	A203849	004	Apr 06, 2015	Mar	NEWA
AB		200MG	A203849	005	Apr 06, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr	CAHN
AB		30MG	A078761	002	May 11, 2012	Apr	CAHN
AB		60MG	A078761	003	May 11, 2012	Apr	CAHN
AB		100MG	A078761	004	May 11, 2012	Apr	CAHN
AB		200MG	A078761	005	May 11, 2012	Apr	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)
MOXIFLOXACIN HYDROCHLORIDE

	+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr	NEWA
		SOLUTION/DROPS;OPHTHALMIC MOXEZA						
AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG
		MOXIFLOXACIN HYDROCHLORIDE						
AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May	NEWA
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb	NEWA
		VIGAMOX						
AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
@		10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
@		10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
@		20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
@		20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
@		20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION
REVEX

@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun	CAHN
@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE

@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
NALOXONE HYDROCHLORIDE							
@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN
@		1MG/ML	A072091	001	Apr 11, 1989	Mar	CAHN
@		1MG/ML	A072092	001	Apr 11, 1989	Mar	CAHN
@		1MG/ML	A072093	001	Apr 11, 1989	Mar	CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr	CAHN
----	--------------------	----------------------------	---------	-----	--------------	-----	------

NAPROXEN

SUSPENSION;ORAL
NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr	CAHN
----	---	----------------	---------	---------	-----	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATETABLET; ORAL
TREXIMET

PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun NEWA
--------------------	-------------------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDETABLET; ORAL
NEBIVOLOL HYDROCHLORIDE

@	ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun DISC	
		EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun NEWA	
@		EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun DISC	
		EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun NEWA	
@		EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun DISC	
		EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun NEWA	
@		EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun DISC	
		EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun NEWA	
@	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC	
AB		EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA	
@		EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC	
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA	
@		EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC	
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA	
@		EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC	
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA	
>A>	@	INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul DISC
>A>		EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul NEWA	
>A>	@	EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul DISC	
>A>		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul NEWA	
>A>	@	EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul DISC	
>A>		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul NEWA	
>A>	@	EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul DISC	
>A>		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul NEWA	

NEFAZODONE HYDROCHLORIDETABLET; ORAL
NEFAZODONE HYDROCHLORIDE

@	IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
@		100MG	A076072	002	Sep 16, 2003	Apr CAHN
@		150MG	A076072	003	Sep 16, 2003	Apr CAHN
@		200MG	A076072	004	Sep 16, 2003	Apr CAHN
@		250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB		100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB		150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB		200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB		250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINEINJECTABLE; IV (INFUSION)
ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar CAHN
---	----------------------	---------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATESOLUTION; INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan NEWA
	10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan NEWA

NEVIRAPINETABLET, EXTENDED RELEASE; ORAL
NEVIRAPINE

AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun NEWA
----	--------------------	-------	---------	-----	--------------	----------

NIACINTABLET, EXTENDED RELEASE; ORAL
NIACIN

>A>	AB	AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul NEWA
>A>	AB		1GM	A203578	002	Jul 24, 2015	Jul NEWA

NIFEDIPINECAPSULE;ORAL
NIFEDIPINE

AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar CAHN
AB		20MG	A202644	002	Apr 25, 2013	Mar CAHN

NILUTAMIDETABLET;ORAL
NILANDRON

@	CONCORDIA PHARMS INC	50MG
+		150MG

N020169	001	Sep 19, 1996	Apr CAHN
N020169	002	Apr 30, 1999	Apr CAHN

NIMODIPINECAPSULE;ORAL
NIMODIPINE

AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan CAHN
>A> AB		SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Jul NEWA

NINTEDANIB ESYLATECAPSULE;ORAL
OFEV

	BOEHRINGER INGELHEIM	EQ 100MG BASE
+		EQ 150MG BASE

N205832	001	Oct 15, 2014	Mar CAIN
N205832	002	Oct 15, 2014	Mar CAIN

NITRIC OXIDEGAS;INHALATION
INOMAX

@ INO 100PPM

N020845	002	Dec 23, 1999	Jun DISC
---------	-----	--------------	----------

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACRODANTIN

AB	ALVOGEN INC	25MG	N016620	003		Jun CTEC
	NITROFURANTOIN					
AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun NEWA
AB		50MG	A091095	002	Jun 18, 2015	Jun NEWA
AB		100MG	A091095	003	Jun 18, 2015	Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun NEWA
----	-----------------	-----------	---------	-----	--------------	----------

NORETHINDRONETABLET;ORAL-28
NOR-QD

AB1	+	ACTAVIS LABS UT INC	0.35MG	N017060	001	Mar CAHN
-----	---	---------------------	--------	---------	-----	----------

NORGESTRELTABLET;ORAL
OVRETTE

@ LABORATOIRE HRA 0.075MG

N017031	001		Jun CAHN
---------	-----	--	----------

NYSTATINCREAM;TOPICAL
NYSTATIN

AT	G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun CMFD
----	------------------	------------------	---------	-----	--	----------

SUSPENSION;ORAL
NYSTATIN

AA	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr CAHN
	@	100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar CMFD
----	------------------	-----------------------	---------	-----	--------------	----------

OINTMENT;TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar CMFD
----	------------------	-----------------------	---------	-----	--------------	----------

OFLOXACINTABLET; ORAL
OFLOXACIN

>D>	@ LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Jul CMFD
>A>	AB	400MG	A076093	003	Sep 02, 2003	Jul CMFD

OLANZAPINETABLET; ORAL
OLANZAPINE

AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr NEWA
	TABLET, ORALLY DISINTEGRATING; ORAL OLANZAPINE					
AB	MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb NEWA
AB		10MG	A203044	002	Feb 20, 2015	Feb NEWA
AB		15MG	A203044	003	Feb 20, 2015	Feb NEWA
AB		20MG	A203044	004	Feb 20, 2015	Feb NEWA
AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb NEWA
AB		10MG	A202937	002	Mar 02, 2015	Feb NEWA
AB		15MG	A202937	003	Mar 02, 2015	Feb NEWA
AB		20MG	A202937	004	Mar 02, 2015	Feb NEWA

OLAPARIBCAPSULE; ORAL
LYNPARZA

	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan CTNA
--	--------------------	------	---------	-----	--------------	----------

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDESPRAY, METERED; INHALATION
STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH; EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May NEWA
---	----------------------	--	---------	-----	--------------	----------

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun NEWA
	PATADAY					
AT	+ ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun CFTG
	PAZEO					
	+ ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan NEWA

>A> OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET; ORAL
TECHNIVIE

>A>	+ ABBVIE INC	12.5MG; 75MG; 50MG	N207931	001	Jul 25, 2015	Jul NEWA
-----	--------------	--------------------	---------	-----	--------------	----------

ONDANSETRONTABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr CAHN
AB		8MG	A078602	002	Feb 24, 2011	Apr CAHN
	ZOFTRAN ODT					
AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar CAHN
AB	+	8MG	N020781	002	Jan 27, 1999	Mar CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun NEWA
AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun CAHN
	@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan DISC
	ZOFTRAN					
AP	+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
	ZOFTRAN PRESERVATIVE FREE					
AP	+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN

SOLUTION;ORAL
ZOFTRAN

AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN
TABLET;ORAL							
ZOFTRAN							
AB		NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN
AB			EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN
AB	+		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN

ORPHENADRINE CITRATEINJECTABLE;INJECTION
NORFLEX

		@ IGI LABS INC	30MG/ML	N013055	001		Apr CAHN
		@ MEDICIS	30MG/ML	N013055	001		Mar DISC
ORPHENADRINE CITRATE							
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD

OXCARBAZEPINESUSPENSION;ORAL
OXCARBAZEPINE

AB		SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr CAHN
----	--	--------------------	-----------	---------	-----	--------------	----------

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN
GEL, METERED;TRANSDERMAL							
GELNIQUE 3%							
	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar CAHN

OXYBUTYNIN CHLORIDEGEL;TRANSDERMAL
GELNIQUE

	+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN
--	---	---------------------	-------------------	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDESOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

AA		ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May NEWA
AA		NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr NEWA
AA		WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun NEWA

TABLET;ORAL
OXAYDO

		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar CTNA
			7.5MG	N202080	002	Jun 17, 2011	Mar CTNA
>D>		EGALET LTD	5MG	N202080	001	Jun 17, 2011	Jul CAHN
			5MG	N202080	001	Jun 17, 2011	May CAHN
>D>			7.5MG	N202080	002	Jun 17, 2011	Jul CAHN
			7.5MG	N202080	002	Jun 17, 2011	May CAHN
>A>		EGALET US INC	5MG	N202080	001	Jun 17, 2011	Jul CAHN
>A>			7.5MG	N202080	002	Jun 17, 2011	Jul CAHN

OXYCODONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar NEWA
AB		VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar NEWA
AB			20MG	A077712	005	Apr 13, 2015	Mar NEWA

OXYMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr NEWA
AB			7.5MG	A203506	002	Apr 24, 2015	Apr NEWA
AB			10MG	A203506	003	Apr 24, 2015	Apr NEWA
AB			15MG	A203506	004	Apr 24, 2015	Apr NEWA
AB			20MG	A203506	005	Apr 24, 2015	Apr NEWA
AB			30MG	A203506	006	Apr 24, 2015	Apr NEWA
AB			40MG	A203506	007	Apr 24, 2015	Apr NEWA

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN

PALBOCICLIB

CAPSULE; ORAL
IBRANCE

	PFIZER INC	75MG	N207103	001	Feb 03,	2015	Feb	NEWA
		100MG	N207103	002	Feb 03,	2015	Feb	NEWA
+		125MG	N207103	003	Feb 03,	2015	Feb	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL
INVEGA

>D>		JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul CFTG
>A>	AB		1.5MG	N021999	006	Aug 26, 2008	Jul CFTG
>D>			3MG	N021999	001	Dec 19, 2006	Jul CFTG
>A>	AB		3MG	N021999	001	Dec 19, 2006	Jul CFTG
>D>	+		6MG	N021999	002	Dec 19, 2006	Jul CFTG
>A>	AB	+	6MG	N021999	002	Dec 19, 2006	Jul CFTG
>D>			9MG	N021999	003	Dec 19, 2006	Jul CFTG
>A>	AB		9MG	N021999	003	Dec 19, 2006	Jul CFTG
>A>		PALIPERIDONE					
>A>	AB	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul NEWA
>A>	AB		3MG	A202645	002	Aug 03, 2015	Jul NEWA
>A>	AB		6MG	A202645	003	Aug 03, 2015	Jul NEWA
>A>	AB		9MG	A202645	004	Aug 03, 2015	Jul NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA TRINZA

	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May NEWA
		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May NEWA
		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May NEWA
+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

@ IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072211	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072212	001	Mar 31, 1988	Mar CAHN
@	2MG/ML	A072213	001	Mar 31, 1988	Mar CAHN

PANOBINOSTAT

CAPSULE; ORAL
FARYDAK

	NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
		15MG	N205353	002	Feb 23, 2015	Feb NEWA
+		20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBINOSTAT LACTATE

CAPSULE; ORAL
FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23,	2015	Mar	CAIN
		EQ 10MG BASE	N205353	001	Feb 23,	2015	Mar	CPOT
		EQ 15MG BASE	N205353	002	Feb 23,	2015	Mar	CAIN
		EQ 15MG BASE	N205353	002	Feb 23,	2015	Mar	CPOT
+		EQ 20MG BASE	N205353	003	Feb 23,	2015	Mar	CAIN
+		EQ 20MG BASE	N205353	003	Feb 23,	2015	Mar	CPOT

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296 001	Jul 14, 2015	Jun NEWA
----	------------	-------------------	-------------	--------------	----------

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN
----	----------------	-------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
BONTRIL

@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan DISC
	PHENDIMETRAZINE TARTRATE					
+	SANDOZ	105MG	N018074	001		Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
DIBENZYLIN

AB	+	CONCORDIA PHARMS INC	10MG	N008708	001	Jun CAHN
----	---	----------------------	------	---------	-----	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA	MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun CMFD
----	------------------	--------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan NEWA
		10%	N207926	002	Jan 15, 2015	Jan NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETH VC PLAIN

>D>	AA	+	ACTAVIS MID ATLANTIC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul CAHN
>A>	AA	+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM

	@	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun DISC
	@	WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun DISC
		PHENYTOIN SODIUM					
AB		AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May NEWA
		INJECTABLE;INJECTION					
		PHENYTOIN SODIUM					
AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb CAHN

PHYTONADIONE

INJECTABLE;INJECTION
AQUAMEPHYTON

	@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr CAHN
	@		10MG/ML	N012223	001		Apr CAHN

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL					
PILOCARPINE HYDROCHLORIDE					
AB	ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004 Mar CAHN

PINDOLOL

TABLET; ORAL					
PINDOLOL					
	@ G AND W LABS INC	5MG	A073661	001	Oct 31, 1993 Apr CAHN
	@	5MG	A073687	001	Feb 26, 1993 Apr CAHN
	@	5MG	A074123	001	Apr 17, 1997 Apr CAHN
	@	10MG	A073661	002	Oct 31, 1993 Apr CAHN
	@	10MG	A073687	002	Feb 26, 1993 Apr CAHN
	@	10MG	A074123	002	Apr 17, 1997 Apr CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION					
MAXAIR					
	@ MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992 Jan DISC

PIRFENIDONE

CAPSULE; ORAL					
ESBRIET					
+	GENENTECH INC	267MG	N022535	001	Oct 15, 2014 Feb CAHN

PIROXICAM

CAPSULE; ORAL					
PIROXICAM					
AB	MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993 May CAHN
AB		20MG	A074118	001	Jun 15, 1993 May CAHN

PODOFILOX

GEL; TOPICAL						
CONDYLOX						
+	ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997 Feb CAHN	
SOLUTION; TOPICAL						
CONDYLOX						
AT	+	ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990 Jan CAHN
PODOFILOX						
AT	BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010 May CAHN	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC					
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE					
AT	ALCON RES LTD	10,000 UNITS/ML; EQ 1MG BASE/ML	A064211	001	Apr 13, 1998 Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET; ORAL					
ICLUSIG					
	ARIAD	EQ 30MG BASE	N203469	003	Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL						
KLOR-CON						
AB	UPSHER SMITH	8MEQ	A203106	001	Jul 10, 2015 Jun NEWA	
AB		10MEQ	A203106	002	Jul 10, 2015 Jun NEWA	
TABLET, EXTENDED RELEASE; ORAL						
POTASSIUM CHLORIDE						
>A>	AB1	ADARE PHARMS INC	20MEQ	A076368	001	Aug 18, 2004 Jul CAHN
>D>	AB1	EURAND	20MEQ	A076368	001	Aug 18, 2004 Jul CAHN
	AB2	MYLAN PHARMS INC	8MEQ	A204662	001	Aug 21, 2014 Feb CPOT
	AB2		10MEQ	A204662	002	Aug 21, 2014 Feb CPOT

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL						
PRAMIPEXOLE DIHYDROCHLORIDE						
>A>	AB	DR REDDYS LABS LTD	0.375MG	A203354	001	Aug 07, 2015 Jul NEWA
>A>	AB		0.75MG	A203354	002	Aug 07, 2015 Jul NEWA
>A>	AB		1.5MG	A203354	003	Aug 07, 2015 Jul NEWA
>A>	AB		3MG	A203354	004	Aug 07, 2015 Jul NEWA
>A>	AB		4.5MG	A203354	005	Aug 07, 2015 Jul NEWA

PREDNICARBATEOINTMENT;TOPICAL
DERMATOP

AB	+	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Apr CAHN
----	---	----------------------	------	---------	-----	--------------	----------

PREGABALINCAPSULE;ORAL
LYRICA

		PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Apr CTEC
			50MG	N021446	002	Dec 30, 2004	Apr CTEC
			75MG	N021446	003	Dec 30, 2004	Apr CTEC
			100MG	N021446	004	Dec 30, 2004	Apr CTEC
			150MG	N021446	005	Dec 30, 2004	Apr CTEC
			200MG	N021446	006	Dec 30, 2004	Apr CTEC
			225MG	N021446	007	Dec 30, 2004	Apr CTEC
	+		300MG	N021446	008	Dec 30, 2004	Apr CTEC

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986	Jun CAHN
	@		500MG	A089221	001	Jul 01, 1986	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	250MG	A089369	001	Aug 14, 1987	Jun CAHN
	@		500MG	A089370	001	Jan 09, 1987	Jun CAHN
	@		750MG	A089371	001	Aug 14, 1987	Jun CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb CAHN
----	---	--------------------	----------------	---------	-----	--------------	----------

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan CAHN

GEL;VAGINAL

CRINONE

		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb CAHN
	+		8%	N020701	002	Jul 31, 1997	Feb CAHN

INJECTABLE;INJECTION

PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar CAHN
----	---	---------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun CAHN
AP	+		50MG/ML	A083312	002		Jun CAHN

SUPPOSITORY;RECTAL

PHENERGAN

	@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr CAHN
	@		25MG	N010926	001		Apr CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar CAHN
AB			25MG	A040673	002	Mar 05, 2008	Mar CAHN
AB			50MG	A040673	003	Mar 05, 2008	Mar CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA
----	--	----------------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	180MG	N011665	001		Jun CFTG
----	---	--------------------	-------	---------	-----	--	----------

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun NEWA
----	--	-------------	-------	---------	-----	--------------	----------

QUAZEPAMTABLET;ORAL
DORAL

@	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun	DISC
---	---------------------	------	---------	-----	--------------	-----	------

QUETIAPINE FUMARATETABLET;ORAL
SEROQUEL

AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May	CAHN
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May	CAHN
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May	CAHN
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May	CAHN
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May	CAHN
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May	CAHN
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr	CAHN
AB			EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr	CAHN
AB			EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr	CAHN
AB			EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr	CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@	CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

@	CYCLE PHARMS LTD	200MG	A083640	001		Jun	CAHN
@		300MG	A085632	001		Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

AB		AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun	NEWA
AB		LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr	NEWA
>A> AB		RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul	NEWA

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

>A> AB		AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul	NEWA
--------	--	---------------	------	---------	-----	--------------	-----	------

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB		WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan	NEWA
----	--	-----------------	------	---------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP	+	CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun	CAHN
----	---	----------------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr	CAHN
@		EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr	CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr	NEWA
AB			1MG	A091517	002	Apr 24, 2015	Apr	NEWA
AB			2MG	A091517	003	Apr 24, 2015	Apr	NEWA

RIBAVIRIN

CAPSULE;ORAL

REBETOL

@ MERCK SHARP DOHME

200MG

N020903 001 Jun 03, 1998 Jun DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB + WARNER CHILCOTT LLC 35MG

N022560 001 Oct 08, 2010 May CFTG

RISEDRONATE SODIUM

AB TEVA PHARMS USA 35MG

A203217 001 May 18, 2015 May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB SUN PHARM INDS LTD 0.5MG

A077542 001 Aug 06, 2010 Apr CAHN

AB 1MG

A077542 002 Aug 06, 2010 Apr CAHN

AB 2MG

A077542 003 Aug 06, 2010 Apr CAHN

AB 3MG

A078474 001 Aug 06, 2010 Apr CAHN

AB 4MG

A078474 002 Aug 06, 2010 Apr CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

JANSSSEN PHARMS

10MG

N022406 001 Jul 01, 2011 Apr CRLD

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB ORCHID HLTHCARE EQ 1.5MG BASE

A090879 001 Jun 10, 2015 May NEWA

AB EQ 3MG BASE

A090879 002 Jun 10, 2015 May NEWA

AB EQ 4.5MG BASE

A090879 003 Jun 10, 2015 May NEWA

AB EQ 6MG BASE

A090879 004 Jun 10, 2015 May NEWA

ROFLUMILAST

TABLET;ORAL

DALIRESP

+ ASTRAZENECA PHARMS 500MCG

N022522 001 Feb 28, 2011 Mar CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB G AND W LABS INC EQ 0.25MG BASE

A077460 001 May 05, 2008 Apr CAHN

AB EQ 0.5MG BASE

A077460 002 May 05, 2008 Apr CAHN

AB EQ 1MG BASE

A077460 003 May 05, 2008 Apr CAHN

AB EQ 2MG BASE

A077460 004 May 05, 2008 Apr CAHN

AB EQ 3MG BASE

A077460 005 May 05, 2008 Apr CAHN

AB EQ 4MG BASE

A077460 006 May 05, 2008 Apr CAHN

AB EQ 5MG BASE

A077460 007 May 19, 2008 Apr CAHN

>A> SACUBITRIL; VALSARTAN

>A> TABLET;ORAL

>A> ENTRESTO

>A> NOVARTIS PHARMS CORP 24MG;26MG

N207620 001 Jul 07, 2015 Jul NEWA

>A> 49MG;51MG

N207620 002 Jul 07, 2015 Jul NEWA

>A> + 97MG;103MG

N207620 003 Jul 07, 2015 Jul NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB PERRIGO PHARMS CO 1MG/72HR

A078830 001 Jan 30, 2015 Mar CAHN

AB PERRIGO R AND D 1MG/72HR

A078830 001 Jan 30, 2015 Jan NEWA

TRANSDERM SCOP

AB + NOVARTIS 1MG/72HR

N017874 001 Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ G AND W LABS INC 5MG

A074537 001 Aug 02, 1996 Apr CAHN

@ 5MG

A074744 001 Jan 27, 1997 Apr CAHN

@ 5MG

A074756 001 Nov 25, 1998 Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
	@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
	@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr CAHN
AB			EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr CAHN
AB			EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr CAHN
			EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr CAHN
			EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr CAHN

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar CFTG
AP		SILDENAFIL CITRATE AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN
			8MG	N022206	002	Oct 08, 2008	Mar CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB		SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr CAHN
AB			10MG	A076285	002	Dec 20, 2006	Apr CAHN
AB			20MG	A076285	003	Dec 20, 2006	Apr CAHN
AB			40MG	A076285	004	Dec 20, 2006	Apr CAHN
AB			80MG	A076285	005	Jun 23, 2006	Apr CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN
		SODIUM CHLORIDE 0.9% EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
	+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN
----	--	--------------------	------------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

>A>	AP	CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul NEWA
>A>	AP	HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul NEWA
>A>	AP	MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul NEWA
	AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
	AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
	AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM POLYSTYRENE SULFONATE

		POWDER;ORAL, RECTAL					
		KALEXATE					
		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar NEWA
		KAYEXALATE					
AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN

SODIUM TETRADECYL SULFATE

		INJECTABLE;INJECTION					
		SOTRADECOL					
>D>		MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul CRLD
>A>	+		20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul CRLD

SOMATROPIN RECOMBINANT

		INJECTABLE;INJECTION					
		NORDITROPIN FLEXPOR					
		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan NEWA
		NORDITROPIN NORDIFLEX					
>D>		NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Jul DISC
>A>	@		30MG/3ML	N021148	007	Mar 10, 2009	Jul DISC
			30MG/3ML	N021148	007	Mar 10, 2009	Mar CMFD
			30MG/3ML	N021148	007	Mar 10, 2009	Jan DISC
		NUTROPIN					
	@	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun DISC
	@		10MG/VIAL	N020168	002	Nov 17, 1993	Jun DISC
BX	+		10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC
		NUTROPIN AQ					
	@	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun DISC
		NUTROPIN AQ NUSPIN					
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun CTNA
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun NEWA
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun CTNA
		NUTROPIN AQ PEN					
	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun NEWA
		ZOMACTON					
BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr CRLD
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar NEWA

SONIDEGIB PHOSPHATE

>A>		CAPSULE;ORAL					
>A>		ODOMZO					
>A>	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Jul NEWA

SOTALOL HYDROCHLORIDE

		SOLUTION;INTRAVENOUS					
		SOTALOL HYDROCHLORIDE					
	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr CAHN
		TABLET;ORAL					
		BETAPACE					
AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar CAHN
AB1			120MG	N019865	005	Apr 20, 1994	Mar CAHN
AB1	+		160MG	N019865	002	Oct 30, 1992	Mar CAHN
AB1			240MG	N019865	003	Oct 30, 1992	Mar CAHN
	@		320MG	N019865	004	Oct 30, 1992	Mar CAHN

SUCCINYLCHOLINE CHLORIDE

		INJECTABLE;INJECTION					
		QUELICIN PRESERVATIVE FREE					
	@	HOSPIRA	100MG/ML	N008845	004		Jun DISC

SUCRALFATE

		TABLET;ORAL					
		SUCRALFATE					
AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTANIL CITRATE

AP	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun CAHN
----	--------------------	-------------------	---------	-----	--------------	----------

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON

AB	+ VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar CAHN
----	------------------------	-----	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT	AKORN	10%	A040215	001	May 25, 1999	Mar CMFD
----	-------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	@ ANI PHARMS INC	200MG/5ML; 40MG/5ML	A070028	001	Jun 02, 1987	Jul CAHN
-----	------------------	---------------------	---------	-----	--------------	----------

>D>	@ TEVA	200MG/5ML; 40MG/5ML	A070028	001	Jun 02, 1987	Jul CAHN
-----	--------	---------------------	---------	-----	--------------	----------

SULFANILAMIDE

CREAM; VAGINAL
SULFANILAMIDE

	@ G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr CAHN
--	--------------------	-----	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATE

TABLET; ORAL
SUMATRIPTAN SUCCINATE

AB	SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr CAHN
----	--------------------	--------------	---------	-----	--------------	----------

AB		EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr CAHN
----	--	--------------	---------	-----	--------------	----------

AB		EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr CAHN
----	--	---------------	---------	-----	--------------	----------

TACROLIMUS

>A> TABLET, EXTENDED RELEASE; ORAL

>A> ENVARUS XR

>A>	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015	Jul NEWA
-----	--------------------	----------------	---------	-----	--------------	----------

>A>		EQ 1MG BASE	N206406	002	Jul 10, 2015	Jul NEWA
-----	--	-------------	---------	-----	--------------	----------

>A>	+	EQ 4MG BASE	N206406	003	Jul 10, 2015	Jul NEWA
-----	---	-------------	---------	-----	--------------	----------

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL
NUCYNTA

+	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May CAHN
---	-------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL
NUCYNTA

	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May CAHN
--	-------------	--------------	---------	-----	--------------	----------

		EQ 75MG BASE	N022304	002	Nov 20, 2008	May CAHN
--	--	--------------	---------	-----	--------------	----------

+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May CAHN
---	--	---------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL
NUCYNTA ER

	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May CAHN
--	-------------	--------------	---------	-----	--------------	----------

		EQ 100MG BASE	N200533	002	Aug 25, 2011	May CAHN
--	--	---------------	---------	-----	--------------	----------

		EQ 150MG BASE	N200533	003	Aug 25, 2011	May CAHN
--	--	---------------	---------	-----	--------------	----------

		EQ 200MG BASE	N200533	004	Aug 25, 2011	May CAHN
--	--	---------------	---------	-----	--------------	----------

+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May CAHN
---	--	---------------	---------	-----	--------------	----------

TELAPREVIR

TABLET; ORAL

INCIVEK

	@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan DISC
--	-----------------	-------	---------	-----	--------------	----------

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May NEWA
----	----------------	-------	---------	-----	--------------	----------

AB		15MG	A201781	002	Jun 04, 2015	May NEWA
----	--	------	---------	-----	--------------	----------

AB		22.5MG	A201781	003	Jun 04, 2015	May NEWA
----	--	--------	---------	-----	--------------	----------

AB		30MG	A201781	004	Jun 04, 2015	May NEWA
----	--	------	---------	-----	--------------	----------

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
AB		20MG	A203691	002	May 08, 2015	Apr	NEWA
AB		100MG	A203691	003	May 08, 2015	Apr	NEWA
AB		140MG	A203691	004	May 08, 2015	Apr	NEWA
AB		180MG	A203691	005	May 08, 2015	Apr	NEWA
AB		250MG	A203691	006	May 08, 2015	Apr	NEWA

TENOFOVIR DISOPROXIL FUMARATETABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar	NEWA
AB	+ GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar	CFTG

TERBINAFINE HYDROCHLORIDETABLET;ORAL
TERBINAFINE HYDROCHLORIDE

@	WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC
---	-----------	---------------	---------	-----	--------------	-----	------

TESTOSTERONEGEL;TRANSDERMAL
ANDROGEL

AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC
AB1	+ TESTIM	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC
AB2	+ AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC
>D>	@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Jul	CMFD
>D>	@	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
>D>	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Jul	CMFD
>D>	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
>A>	AB1	25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul	CMFD
>A>	AB1	50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul	CMFD
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC
AB2	VOGELXO						
AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC
>D>	+ ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul	CFTG
>A>	AB	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul	CFTG
>D>	+ FORTESTA						
>A>	AB	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul	CFTG
>A>	AB	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul	CFTG
>A>	TESTOSTERONE						
>A>	AB	ACTAVIS LABS UT INC	A204571	001	Aug 05, 2015	Jul	NEWA
>A>	AB	PERRIGO ISRAEL	A204268	001	Aug 04, 2015	Jul	NEWA

TETRABENAZINETABLET;ORAL
XENAZINE

	VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Feb	CAHN
+		25MG	N021894	002	Aug 15, 2008	Feb	CAHN

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
ACHROMYCIN V

AB	+ HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD
	TETRACYCLINE HYDROCHLORIDE						
	@ IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC
	@	500MG	A060704	002		Apr	DISC

THEOPHYLLINE

TABLET; ORAL

THEOLAIR

@ MEDICIS

125MG

A086399 001

Mar DISC

@

250MG

A086399 002

Mar DISC

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB MYLAN PHARMS INC

400MG

A040595 001 Apr 21, 2006

May CAHN

AB +

600MG

A040560 002 Apr 21, 2006

May CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

+ EUROHLTH INTL SARL

15MG/VIAL

A075547 001 Apr 02, 2001

May CRLD

TIGECYCLINE

INJECTABLE; IV (INFUSION)

TIGECYCLINE

AP SANDOZ INC

50MG/VIAL

A091620 001 May 27, 2015

May NEWA

TYGACIL

AP + PF PRISM CV

50MG/VIAL

N021821 001 Jun 15, 2005

May CFTG

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

AT2 + BAUSCH AND LOMB

EQ 0.5% BASE

N021516 001 Jun 04, 2004

Apr CFTG

TIMOLOL MALEATE

AT1 AKORN

EQ 0.5% BASE

A074466 001 Mar 25, 1997

Apr CTEC

AT1

EQ 0.5% BASE

A074516 001 Mar 25, 1997

Apr CTEC

AT1 ALCON RES LTD

EQ 0.5% BASE

A074262 001 Apr 28, 1995

Apr CTEC

AT2 APOTEX INC

EQ 0.5% BASE

A204936 001 Apr 17, 2015

Apr NEWA

AT1 BAUSCH AND LOMB

EQ 0.5% BASE

A074776 001 Mar 25, 1997

Apr CTEC

AT1 FDC LTD

EQ 0.5% BASE

A077259 002 Apr 30, 2008

Apr CTEC

AT1 HI TECH PHARMA

EQ 0.5% BASE

A075163 001 Sep 10, 2002

Apr CTEC

AT1 PACIFIC PHARMA

EQ 0.5% BASE

A074747 001 Mar 25, 1997

Apr CTEC

AT1 WOCKHARDT

EQ 0.5% BASE

A078771 002 Sep 28, 2009

Apr CTEC

TIMOPTIC

AT1 + ATON

EQ 0.5% BASE

N018086 002

Apr CTEC

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

>A> AB EDENBRIDGE PHARMS

250MG

A203808 001 Aug 04, 2015

Jul NEWA

>A> AB

500MG

A203808 002 Aug 04, 2015

Jul NEWA

TOBRAMYCIN

SOLUTION; INHALATION

KITABIS PAK

AN PULMOFLOW INC

300MG/5ML

N205433 001 Dec 02, 2014

Feb CTEC

TOBRAMYCIN

AN AMNEAL PHARMS

300MG/5ML

A205501 001 Jul 13, 2015

Jun NEWA

SOLUTION/DROPS; OPHTHALMIC

TOBREX

AT + ALCON LABS INC

0.3%

N050541 001

Mar CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

>D> AP

+ HOSPIRA

EQ 40MG BASE/ML

A063116 001 May 18, 1992

Jul CTNA

@ IGI LABS INC

EQ 10MG BASE/ML

A063119 001 Oct 31, 1994

Mar CAHN

@

EQ 40MG BASE/ML

A063120 001 Oct 31, 1994

Mar CAHN

@

EQ 40MG BASE/ML

A063121 001 Oct 31, 1994

Mar CAHN

@

EQ 40MG BASE/ML

A063122 001 Oct 31, 1994

Mar CAHN

TOBRAMYCIN SULFATE (PHARMACY BULK)

>D> AP

+ FRESENIUS KABI USA

EQ 40MG BASE/ML

A065120 001 Nov 29, 2002

Jul CRLD

>A>

+

EQ 40MG BASE/ML

A065120 001 Nov 29, 2002

Jul CTEC

>A> AP

+

EQ 40MG BASE/ML

A065120 001 Nov 29, 2002

Jul CRLD

>A>

@ HOSPIRA

EQ 40MG BASE/ML

A063116 001 May 18, 1992

Jul DISC

>A> AP

EQ 40MG BASE/ML

A063116 001 May 18, 1992

Jul CTNA

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr CAHN
@	250MG	N018894	002	Nov 02, 1984	Apr CAHN
@	500MG	N018894	003	Nov 02, 1984	Apr CAHN

TOLCAPONETABLET; ORAL
TASMAR

AB	+ VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG
AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA

TOLMETIN SODIUMTABLET; ORAL
TOLMETIN SODIUM

@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May CAHN
@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr CAHN

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
TOLTERODINE TARTRATE

>A> AB	TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul NEWA
>A> AB		4MG	A203016	002	Aug 11, 2015	Jul NEWA

TABLET; ORAL

TOLTERODINE TARTRATE

AB	IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
AB		2MG	A077006	002	Feb 23, 2015	Feb NEWA

TOPIRAMATETABLET; ORAL
TOPIRAMATE

AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr CAHN
AB		100MG	A076327	002	Mar 27, 2009	Apr CAHN
AB		200MG	A076327	003	Mar 27, 2009	Apr CAHN
	@ WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr DISC
	@	50MG	A090353	002	Sep 01, 2010	Apr DISC
	@	100MG	A090353	003	Sep 01, 2010	Apr DISC
	@	200MG	A090353	004	Sep 01, 2010	Apr DISC
	TOPIRAMATE					
	@ HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May DISC
	@	50MG	A091185	002	Nov 25, 2013	May DISC
	@	100MG	A091185	003	Nov 25, 2013	May DISC
	@	200MG	A091185	004	Nov 25, 2013	May DISC

TOPOTECAN HYDROCHLORIDECAPSULE; ORAL
HYCAMTINNOVARTIS PHARMS CORP EQ 0.25MG BASE
+ EQ 1MG BASE

N020981	001	Oct 11, 2007	Mar CAHN
N020981	002	Oct 11, 2007	Mar CAHN

INJECTABLE; INJECTION
HYCAMTIN

AP	+ NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN
AP	TOPOTECAN HYDROCHLORIDE					
	CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May CAHN

TORSEMIDEINJECTABLE; INJECTION
TORSEMIDE

@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan DISC
@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan DISC
@ LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan DISC
@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan DISC

TRAMETINIB DIMETHYL SULFOXIDETABLET;ORAL
MEKINIST

	NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar CAHN
		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar CAHN
+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar CAHN

TRANEXAMIC ACIDINJECTABLE;INJECTION
TRANEXAMIC ACID

AP	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr CMFD
----	--------------------	----------	---------	-----	--------------	----------

TRANLYCYPROMINE SULFATETABLET;ORAL
PARNATE

AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun CAHN
----	---	----------------------	--------------	---------	-----	--------------	----------

TRAVOPROSTSOLUTION/DROPS;OPHTHALMIC
IZBA

>D>							
>D>	+	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Jul DISC
>A>	@		0.003%	N204822	001	May 15, 2014	Jul DISC
		TRAVATAN Z					
AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun CTEC
		TRAVOPROST					
AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun NEWA

TRAZODONE HYDROCHLORIDETABLET;ORAL
DESYREL

@	PRAGMA PHARMS LLC	50MG	N018207	001		May CAHN
@		100MG	N018207	002		May CAHN
@		150MG	N018207	003	Mar 25, 1985	May CAHN
@		300MG	N018207	004	Nov 07, 1988	May CAHN

TABLET, EXTENDED RELEASE;ORAL

	OLEPTRO					
@	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar DISC
@		300MG	N022411	002	Feb 02, 2010	Mar DISC

TRETINOINCREAM;TOPICAL
RENOVA

	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr CAHN

RETIN-A

AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr CAHN
----	---	----------------------	------	---------	-----	--	----------

GEL;TOPICAL
ATRALIN

>D>	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul CTEC
>A>	AB	+	0.05%	N022070	001	Jul 26, 2007	Jul CTEC

TRETINOIN

>A>	AB	SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul NEWA
-----	----	------------------	-------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr CMFD
AT		0.1%	A089798	001	May 31, 1991	Apr CMFD

TRIDERM

AT	CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar NEWA
AT		0.5%	A088042	003	Mar 25, 2015	Mar NEWA

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar CMFD
----	------------------	------	---------	-----	--------------	----------

OINTMENT;TOPICAL

KENALOG

AT	DELCOR ASSET CORP	0.025%	N011600	003		Mar CMFD
AT		0.1%	N011600	001		Mar CMFD

SPRAY; TOPICAL						
KENALOG						
AT	+ RANBAXY	0.147MG/GM	N012104	001		Mar CFTG
TRIAMCINOLONE ACETONIDE						
AT	PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar NEWA

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

CONCORDIA PHARMS INC

50MG

N013174 001

Apr CAHN

+

100MG

N013174 002

Apr CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

AB + ODYSSEY PHARMS

EQ 50MG BASE

N016792 002

Jun CRLD

AB EQ 100MG BASE

N016792 003 Sep 15, 1982

Jun CRLD

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

VAGILIA

>A> @ G AND W LABS INC

3.7%; 2.86%; 3.42%

A088821 001 Nov 09, 1987

Jul CAHN

>D> @ TEVA

3.7%; 2.86%; 3.42%

A088821 001 Nov 09, 1987

Jul CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+ ACTAVIS LABS UT INC

EQ 3.75MG BASE/VIAL

N020715 001 Jun 15, 2000

Jan CAHN

+

EQ 11.25MG BASE/VIAL

N021288 001 Jun 29, 2001

Jan CAHN

+

EQ 22.5MG BASE/VIAL

N022437 001 Mar 10, 2010

Jan CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

@ ALLERGAN

60MG

N022103 001 Aug 03, 2007

May DISC

TROSPIUM CHLORIDE

AB ACTAVIS LABS FL INC

60MG

A091289 001 Oct 12, 2012

Jun CRLD

AB +

60MG

A091289 001 Oct 12, 2012

May CRLD

AB SANDOZ INC

60MG

A091635 001 Apr 29, 2015

Apr NEWA

TABLET; ORAL

SANCTURA

@ ALLERGAN

20MG

N021595 001 May 28, 2004

May DISC

TROSPIUM CHLORIDE

AB GLENMARK GENERICS

20MG

A091575 001 Aug 13, 2010

Jun CRLD

AB +

20MG

A091575 001 Aug 13, 2010

May CRLD

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+ R-TECH UENO LTD

0.15%

N021214 001 Aug 03, 2000

May CAHN

+ SUCAMPO PHARMA LLC

0.15%

N021214 001 Aug 03, 2000

Jan CAHN

URSODIOL

CAPSULE; ORAL

ACTIGALL

@ ACTAVIS LABS UT INC

150MG

N019594 001 Dec 31, 1987

Mar CAHN

AB +

300MG

N019594 002 Dec 31, 1987

Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB HETERO LABS LTD V

EQ 500MG BASE

A203047 001 Apr 08, 2015

Mar NEWA

AB

EQ 1GM BASE

A203047 002 Apr 08, 2015

Mar NEWA

AB SUN PHARM INDS LTD

EQ 500MG BASE

A076588 001 Jan 31, 2007

Apr CAHN

AB

EQ 1GM BASE

A076588 002 Jan 31, 2007

Apr CAHN

VALPROIC ACID

CAPSULE;ORAL						
VALPROIC ACID						
AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan CAHN
CAPSULE, DELAYED RELEASE;ORAL						
STAVZOR						
	@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan CAHN
	@	250MG	N022152	002	Jul 29, 2008	Jan CAHN
	@	500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTAN

TABLET;ORAL						
VALSARTAN						
AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
AB		80MG	A204821	002	Jun 09, 2015	May NEWA
AB		160MG	A204821	003	Jun 09, 2015	May NEWA
AB		320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL						
VANCOMYCIN HYDROCHLORIDE						
AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA
INJECTABLE;INJECTION						
VANCOLED						
	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL						
STAXYN						
AB	+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
VARDENAFIL HYDROCHLORIDE						
AB	WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
VENLAFAXINE HYDROCHLORIDE						
AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN
TABLET;ORAL						
VENLAFAXINE HYDROCHLORIDE						
AB	YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB		EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB		EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB		EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB		EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
VERELAN						
AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB		240MG	N019614	002	May 29, 1990	Apr CAHN
	+	360MG	N019614	004	May 10, 1996	Apr CAHN
VERELAN PM						
AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr CAHN
INJECTABLE;INJECTION						
ISOPTIN						
	@ MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN
TABLET;ORAL						
ISOPTIN						
	@ MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
	@	80MG	N018593	001	Mar 08, 1982	Apr CAHN
	@	120MG	N018593	002	Mar 08, 1982	Apr CAHN

VERTEPORFININJECTABLE;INJECTION
VISUDYNE

+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar CAHN
---	--------------------	-----------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDETABLET;ORAL
VIIBRYD

+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar CAHN
		20MG	N022567	002	Jan 21, 2011	Mar CAHN
		40MG	N022567	003	Jan 21, 2011	Mar CAHN

ZAFIRLUKASTTABLET;ORAL
ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb CAHN

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

>D>	AP	AGILA SPECLTS	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul CAHN
	AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr NEWA
	AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar NEWA
>A>	AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul CAHN
	AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CPOT

ZOLPIDEM TARTRATETABLET;ORAL
ZOLPIDEM TARTRATE

	@	HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
	@		10MG	A078129	002	Apr 30, 2008	Mar DISC
AB		SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN
AB			10MG	A078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL
INTERMEZZO

AB		PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
AB	+		3.5MG	N022328	002	Nov 23, 2011	May CFTG
		ZOLPIDEM TARTRATE					
AB		NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
AB			3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDECAPSULE;ORAL
ZONISAMIDE

AB		BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB			50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB			100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
 ACETAMINOPHEN

SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011	Apr CAHN
@	650MG	A090205	001	Nov 18, 2009	Apr CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL
 SHADE UVAGUARD

+ BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992	Mar CAHN
------------------------	------------	---------	-----	--------------	----------

BUDESONIDE

SPRAY, METERED;NASAL
 RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015	Mar NEWA
----------------------	---------------	---------	-----	--------------	----------

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL
 LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001	Mar CAHN
------------------------	----	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL
 CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES	5MG	N022429	001	Jul 23, 2009	Jan CAHN
+	10MG	N022429	004	Jul 23, 2009	Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES	5MG	N022429	003	Jul 23, 2009	Jan CAHN
+	10MG	N022429	002	Jul 23, 2009	Jan CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015	Jul NEWA
>A>		10MG	A090760	003	Aug 05, 2015	Jul NEWA
	SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007	Apr CAHN
		10MG	A077498	002	Dec 27, 2007	Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007	Apr CAHN
	10MG	A077498	004	Dec 27, 2007	Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015	Jul NEWA
>A>		10MG	A090760	004	Aug 05, 2015	Jul NEWA

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015	Feb NEWA
	10MG	A091116	002	Feb 19, 2015	Feb NEWA
SANDOZ	5MG	A078692	001	Feb 14, 2008	Feb CTNA
+	10MG	A078692	002	Feb 14, 2008	Feb CTNA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015	Feb NEWA
	10MG	A091116	004	Feb 19, 2015	Feb NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL
 CHLOR-TRIMETON

@ BAYER HEALTHCARE LLC	8MG	N007638	001		Mar CAHN
+	12MG	N007638	002		Mar CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
 CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC	8MG;120MG	N018397	001		Mar CAHN
------------------------	-----------	---------	-----	--	----------

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

>A>	@ ANI PHARMS INC	1.34MG	A073282	002	Dec 03, 1992	Jul CAHN
>D>	@ TEVA	1.34MG	A073282	002	Dec 03, 1992	Jul CAHN

CLOTTRIMAZOLE

CREAM;VAGINAL
GYNE-LOTTRIMIN

+ BAYER HEALTHCARE LLC 1% N018052 002 Nov 30, 1990 Mar CAHN
GYNE-LOTTRIMIN 3

+ BAYER HEALTHCARE LLC 2% N020574 001 Nov 24, 1998 Mar CAHN

CREAM, TABLET;TOPICAL, VAGINAL
GYNE-LOTTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,100MG N020289 002 Apr 26, 1993 Mar CAHN

TABLET;VAGINAL
GYNE-LOTTRIMIN

+ BAYER HEALTHCARE LLC 100MG N017717 002 Nov 30, 1990 Mar CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

SUN PHARM INDS LTD 10MG A090283 001 Nov 17, 2009 Apr CAHN
20MG A090283 002 Nov 17, 2009 Apr CAHN

PEPCID AC

>A> J AND J CONSUMER INC 10MG N020325 001 Apr 28, 1995 Jul CAHN
>A> + 20MG N020325 002 Sep 23, 2003 Jul CAHN
>D> MCNEIL CONS 10MG N020325 001 Apr 28, 1995 Jul CAHN
>D> + 20MG N020325 002 Sep 23, 2003 Jul CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL 60MG;120MG A090818 001 Jan 29, 2015 Jan NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC 600MG;60MG A091071 001 May 27, 2015 May NEWA
1.2GM;120MG A091071 002 May 27, 2015 May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES EQ 200MG FREE ACID AND POTASSIUM SALT A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES 200MG N021472 001 Oct 18, 2002 Jan CAHN

IBUPROFEN SODIUM

TABLET;ORAL

IBUPROFEN SODIUM

>A> PERRIGO R AND D EQ 200MG BASE A206581 001 Aug 03, 2015 Jul NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB EQ 0.035% BASE N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD 1.5MG A202246 001 Jun 05, 2015 May NEWA

OC PHARMA 1.5MG A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES 1MG

N021855 001 Aug 04, 2005 Jan CAHN

+ 2MG

N021855 002 Aug 04, 2005 Jan CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006 Apr CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008 Mar CAHN

SYRUP;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N020641 003 Nov 19, 2003 Mar CAHN

LORATADINE

>A> TARO 1MG/ML

A201865 001 Jul 31, 2015 Jul NEWA

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD 10MG

A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS

+ BAYER HEALTHCARE LLC 5MG

N021993 001 Dec 12, 2006 Mar CAHN

LORATADINE REDIDOSE

SUN PHARM INDS LTD 10MG

A077153 001 Apr 11, 2007 Apr CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+ BAYER HEALTHCARE LLC 5MG;120MG

N019670 002 Nov 27, 2002 Mar CAHN

CLARITIN-D 24 HOUR

+ BAYER HEALTHCARE LLC 10MG;240MG

N020470 002 Nov 27, 2002 Mar CAHN

LORATADINE AND PSEUDOEPHEDRINE SULFATE

SUN PHARM INDS LTD 10MG;240MG

A076557 001 Sep 22, 2004 Apr CAHN

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BANNER LIFE SCIENCES EQ 200MG BASE

N021920 001 Feb 17, 2006 Jan CAHN

CATALENT EQ 200MG BASE

A202807 001 Feb 13, 2015 Feb NEWA

OHM LABS INC EQ 200MG BASE

A202807 001 Feb 13, 2015 Jun CAHN

TABLET;ORAL

NAPROXEN SODIUM

SUN PHARM INDS LTD EQ 200MG BASE

A091183 001 May 20, 2011 Apr CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

@ IVAX SUB TEVA PHARMS EQ 2MG BASE

A076880 001 Feb 18, 2009 Mar DISC

@ EQ 4MG BASE

A077850 001 Feb 18, 2009 Mar DISC

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

>A> PERRIGO R AND D EQ 20MG BASE

A204152 001 Jul 30, 2015 Jul NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+ BAYER HEALTHCARE LLC 20MG;1.1GM

N022281 001 Dec 01, 2009 Mar CAHN

FOR SUSPENSION;ORAL				
ZEGERID OTC				
+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283 001	Jun 17, 2013 Mar CAHN
<u>OXYMETAZOLINE HYDROCHLORIDE</u>				
SOLUTION/DROPS;OPHTHALMIC				
OCUCLEAR				
	BAYER HEALTHCARE LLC	0.025%	N018471 001	May 30, 1986 Mar CAHN
<u>POLYETHYLENE GLYCOL 3350</u>				
FOR SOLUTION;ORAL				
MIRALAX				
+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015 001	Oct 06, 2006 Mar CAHN
	POLYETHYLENE GLYCOL 3350			
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071 001	Dec 28, 2012 Jan CAHN
<u>PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
TABLET, EXTENDED RELEASE;ORAL				
PSEUDOEPHEDRINE HYDROCHLORIDE				
	SUN PHARM INDS LTD	120MG	A077442 001	Sep 28, 2005 Apr CAHN
<u>RANITIDINE HYDROCHLORIDE</u>				
TABLET;ORAL				
RANITIDINE HYDROCHLORIDE				
@	SUN PHARM INDS LTD	EQ 75MG BASE	A075132 001	Jan 14, 2000 Apr CAHN
@	WOCKHARDT	EQ 75MG BASE	A078884 001	Jul 31, 2008 Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2015

NO JULY 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9056100	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	>A> 8445543	Jul 12, 2027	U-1078		>A> NP	Jul 15, 2018
	>A> 8703820	Mar 12, 2023	U-1078			
	>A> 8729127	Mar 12, 2023	U-1078			
	>A> 8785420	Dec 23, 2022	U-1078			
	>A> 8909305	Dec 23, 2022	U-1078			
	>A> 8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	>A> 8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	>A> 8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	>A> 8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	>A> 8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005 >A>	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006 >A>	8637079	Jun 04, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8778924	Dec 08, 2026	DS DP U-897			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 003					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	8993761	Sep 25, 2022	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			PED	Dec 02, 2017
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001				>A> NP	Jul 29, 2018
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	001				NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236	001	8163723	Aug 29, 2023	U-77	NPP	Feb 20, 2018
		8163723	Aug 29, 2023	U-81		
		8163723	Aug 29, 2023	U-644		
		8163723	Aug 29, 2023	U-707		
		8163723	Aug 29, 2023	U-1667		
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	001	>A> 9066936	Mar 26, 2028	DP		
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	002	>A> 9066936	Mar 26, 2028	DP		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	001	>A> 9066936	Mar 26, 2028	DP		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	002	>A> 9066936	Mar 26, 2028	DP		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819	001	8895070	Jun 03, 2029	U-124		
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308	001	8937062	Nov 13, 2029	U-80		
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	8933120	Mar 16, 2025	DP		
		8933127	Mar 16, 2025	DP		
<u>BIMATOPROST - LATISSE</u>						
N 022369	001	7351404	May 25, 2024	U-939	Y	
		7388029	Jan 21, 2022	U-938	Y	
		8541466	Jan 31, 2021	U-1217		
		8986715	Jan 15, 2023	U-1217		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	001	>A> 7888362	Feb 23, 2027	DS	>A> NCE	Jul 10, 2020
		>A> 8349840	Apr 12, 2026	DP U-1529		
		>A> 8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	002	>A> 7888362	Feb 23, 2027	DS	>A> NCE	Jul 10, 2020
		>A> 8349840	Apr 12, 2026	DP U-1529		
		>A> 8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	003	>A> 7888362	Feb 23, 2027	DS	>A> NCE	Jul 10, 2020
		>A> 8349840	Apr 12, 2026	DP U-1529		
		>A> 8618109	Apr 12, 2026	U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	004	>A> 7888362	Feb 23, 2027	DS	>A> NCE	Jul 10, 2020
		>A> 8349840	Apr 12, 2026	DP U-1529		
		>A> 8618109	Apr 12, 2026	U-543		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	>A> 7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
	>A> 8349840	Apr 12, 2026	DP U-1529			
	>A> 8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	>A> 7888362	Feb 23, 2027	DS		>A> NCE	Jul 10, 2020
	>A> 8349840	Apr 12, 2026	DP U-1529			
	>A> 8618109	Apr 12, 2026	U-543			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026 001					>A> ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026 002					>A> ODE	Jan 13, 2022
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	>A> 6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	>A> 6130208	Jun 29, 2018	DP U-1715			
	>A> 8680052	Mar 09, 2033	U-1715			
	>A> 8759316	May 13, 2029	U-1715			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1645			
	>A> 9089607	Dec 26, 2028	DP U-1720			
	>A> 9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					>A> I-712	Jul 24, 2018
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323 001	>A> 6248363	Nov 23, 2019	DP U-1716			
	>A> 6383471	Apr 06, 2019	DP U-1716			
	>A> 9066942	Jan 03, 2032	U-1716			
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	001				>A> NCE	Jul 24, 2020
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002				>A> NCE	Jul 24, 2020
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001				ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	001				M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	002				M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001	6037157	Jun 26, 2016	U-1635		
		6703403	Jun 26, 2016	U-1635		
		7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP		
		8188104	May 17, 2029	DS DP	U-1636	
		8268349	Aug 25, 2024	DP		
		8399015	Aug 25, 2024	DP		
		8420596	Apr 10, 2031	DS DP		
		8466159	Sep 04, 2032		U-1637	
		8492386	Sep 04, 2032		U-1637	
		8501238	Sep 17, 2028	DS DP	U-1636	
		8642538	Sep 10, 2029	DS DP	U-1638	
		8680106	Sep 04, 2032		U-1637	
		8685984	Sep 04, 2032		U-1637	
		8686026	Jun 09, 2031	DP		
		8691938	Apr 13, 2032	DS DP		
		9006387	Jun 10, 2030		U-1687	
		9044480	Apr 10, 2031		U-1638	
<u>DEFERASIROX - EXJADE</u>						
N 021882	001				ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882	002				ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882	003				ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910	001	6465504	Apr 05, 2019	DS DP		
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - JADENU</u>						
N 206910	002	6465504	Apr 05, 2019	DS DP		
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - JADENU</u>						
N 206910	003	6465504	Apr 05, 2019	DS DP		
		6596750	Jun 24, 2017	DS	U-735	
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333	001	7622130	Dec 10, 2027		U-1690	
		7754230	Dec 10, 2027		U-1690	
		8101593	Mar 02, 2030	DP		
		8242294	May 16, 2028	DS		
		8298556	Aug 03, 2025		U-1690	
		8367649	Mar 02, 2030	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9066913	Oct 17, 2027	DP U-1488			
	>A> 9101591	Oct 17, 2027	DP U-1488			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694 003					>A> PC	Jan 11, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	>A> 6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 6280959	Oct 30, 2018	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052994	Aug 01, 2027	DP U-1714			
	8062665	Aug 01, 2027	DP U-1714			
	8071129	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	>A> 6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 6280959	Oct 30, 2018	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	8052993	Aug 01, 2027	DP U-1714			
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8062665	Aug 01, 2027	DP U-1714			
	8071129	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	>A> 6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 6280959	Oct 30, 2018	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	8052993	Aug 01, 2027	DP U-1714			
	8052994	Aug 01, 2027	DP U-1714			
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 6280959	Oct 30, 2018	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7332481	May 24, 2021	U-1714			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	8052993	Aug 01, 2027	DP U-1714			
	8052994	Aug 01, 2027	DP U-1714			
	8062665	Aug 01, 2027	DP U-1714			
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005					D-149 I-711	Jun 11, 2018 Jun 11, 2018
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					M-160 M-161	Jun 26, 2018 Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					M-160 M-161	Jun 26, 2018 Jun 26, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	>A> 9056170	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	>A> 9056170	Nov 23, 2024	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001 >A>	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002 >A>	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
>A>	9095706	Jan 17, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GEFITINIB - IRESSA</u>						
N 206995 001	>A> 5770599	May 05, 2017	DS DP U-1403		>A> NP	Jul 13, 2018
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004					M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	>A> 9060940	Oct 30, 2021	U-1556			
	>A> 9084816	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	>A> 9095614	Aug 24, 2027	U-1556			
	>A> 9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	>A> 9060940	Oct 30, 2021	U-1556			
	>A> 9084816	Aug 24, 2027	DP			
	>A> 9095614	Aug 24, 2027	U-1556			
	>A> 9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	>A> 9060940	Oct 30, 2021	U-1556			
	>A> 9084816	Aug 24, 2027	DP			
	>A> 9095614	Aug 24, 2027	U-1556			
	>A> 9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	>A> 9060940	Oct 30, 2021	U-1556			
	>A> 9084816	Aug 24, 2027	DP			
	>A> 9095614	Aug 24, 2027	U-1556			
	>A> 9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2021	DP			
	>A> 9060940	Oct 30, 2021	U-1556			
	>A> 9084816	Aug 24, 2027	DP			
	>A> 9095614	Aug 24, 2027	U-1556			
	>A> 9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2021	DP			
	>A> 9060940	Oct 30, 2021	U-1556			
	>A> 9084816	Aug 24, 2027	DP			
	>A> 9095614	Aug 24, 2027	U-1556			
	>A> 9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	>A> 9060940	Oct 30, 2021	U-1556			
	>A> 9084816	Aug 24, 2027	DP			
	>A> 9095614	Aug 24, 2027	U-1556			
	>A> 9095615	Aug 24, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
>A>	9072742	Jan 16, 2031	U-1674			
>A>	9074254	Dec 28, 2031	U-1674			
>A>	9074255	Dec 17, 2030	U-1674			
>A>	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
>A>	9072742	Jan 16, 2031	U-1674			
>A>	9074254	Dec 28, 2031	U-1674			
>A>	9074255	Dec 17, 2030	U-1674			
>A>	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
>A>	9072742	Jan 16, 2031	U-1674			
>A>	9074254	Dec 28, 2031	U-1674			
>A>	9074255	Dec 17, 2030	U-1674			
>A>	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
>A>	9072742	Jan 16, 2031	U-1674			
>A>	9074254	Dec 28, 2031	U-1674			
>A>	9074255	Dec 17, 2030	U-1674			
>A>	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
>A>	9072742	Jan 16, 2031	U-1674			
>A>	9074254	Dec 28, 2031	U-1674			
>A>	9074255	Dec 17, 2030	U-1674			
>A>	9074256	Feb 10, 2031	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
>A>	9072742	Jan 16, 2031	U-1674			
>A>	9074254	Dec 28, 2031	U-1674			
>A>	9074255	Dec 17, 2030	U-1674			
>A>	9074256	Feb 10, 2031	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	>A> 9072742	Jan 16, 2031	U-1674			
	>A> 9074254	Dec 28, 2031	U-1674			
	>A> 9074255	Dec 17, 2030	U-1674			
	>A> 9074256	Feb 10, 2031	U-1674			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	>A> 8658673	Jun 02, 2020	DS DP U-1168			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
	>A> 9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
	>A> 9089471	Apr 23, 2030	U-55			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	>A> 9078925	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	>A> 7495103	May 20, 2027	DS DP		>A> NCE	Jul 02, 2020
	>A> 8324242	Apr 18, 2027	U-1311		>A> ODE	Jul 02, 2022
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8507534	Sep 20, 2030	DS DP			
	>A> 8653103	Dec 04, 2028	DP			
	>A> 8716338	Nov 08, 2026	DP U-1718			
	>A> 8741933	Nov 08, 2026	U-1717			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8846718	Dec 04, 2028	U-1717			
	>A> 8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	>A> 9089587	Mar 13, 2034	U-1631			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001	9066856	Oct 23, 2033	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					M-159	May 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	8821927	Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	>A> 9085573	Mar 21, 2028	DS DP U-1470			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517 9056120	Oct 04, 2019 Apr 11, 2023	DS U-1211 U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286 7612208 9006256	Oct 19, 2021 Sep 19, 2026 Jul 27, 2027	DS DP DS DP U-1695		NCE ODE	Feb 13, 2020 Feb 13, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286 7612208 9006256	Oct 19, 2021 Sep 19, 2026 Jul 27, 2027	DS DP DS DP U-1695		NCE ODE	Feb 13, 2020 Feb 13, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					I-703	Jan 30, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-703	Jan 30, 2018
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	RE45573	Jun 23, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	9040088	Apr 22, 2024	U-755			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001 >A>	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002 >A>	9060941	Sep 19, 2023	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
	>A> 9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
	>A> 9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
	>A> 9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
	>A> 9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
	>A> 9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
	>A> 9066869	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
>A>	9066869	Dec 16, 2019	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028		U-1682		
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032		U-1664		
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028		U-1643		
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	>A> 9084802	May 12, 2031		U-282		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP	U-702		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029		U-1640		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	>A> 9073933	Mar 30, 2025	DS			
	>A> 9084729	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	>A> 9073933	Mar 30, 2025	DS			
	>A> 9084729	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	>A> 9073933	Mar 30, 2025	DS			
	>A> 9084729	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	>A> 5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	>A> 5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	>A> 6060499	Aug 14, 2017	DP U-1719			
	>A> 6060499*PED	Feb 14, 2018				
	>A> 6586458	Aug 14, 2017	DP U-1719			
	>A> 6586458*PED	Feb 14, 2018				
	>A> 7332183	Oct 02, 2025	DP U-1719			
	>A> 7332183*PED	Apr 02, 2026				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027			U-1634	
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031			U-1634	
	8912187	Mar 12, 2024	U-1634			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP	U-1703		
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025		U-1702		
	8044046	Nov 10, 2023		U-1702		
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP	U-1702		
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	>A> 6037157	Jun 26, 2016	U-1635		>A> NCE	Dec 19, 2019
	>A> 6037157*PED	Dec 26, 2016			>A> NP	Jul 24, 2018
	>A> 6703403	Jun 26, 2016	U-1635			
	>A> 6703403*PED	Dec 26, 2016				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	>A> 7148359	Jul 19, 2019	DP			
	>A> 7148359*PED	Jan 19, 2020				
	>A> 7364752	Nov 10, 2020	DP			
	>A> 7364752*PED	May 10, 2021				
	>A> 8268349	Aug 25, 2024	DP			
	>A> 8268349*PED	Feb 25, 2025				
	>A> 8399015	Aug 25, 2024	DP			
	>A> 8399015*PED	Feb 25, 2025				
	>A> 8420596	Apr 10, 2031	DS DP			
	>A> 8420596*PED	Oct 10, 2031				
	>A> 8642538	Sep 10, 2029	DS DP U-1638			
	>A> 8686026	Jun 09, 2031	DP			
	>A> 8691938	Apr 13, 2032	DS DP			
	>A> 9006387	Jun 10, 2030			U-1687	
	>A> 9044480	Apr 10, 2031			U-1638	
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033			U-1511	
	9050309	Jan 04, 2033	DS			
<u>OMEPRazole - OMEPRazole</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>OSPemifene - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031			U-1644	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	>A> 9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	>A> 9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	>A> 9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	>A> 9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	>A> 9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	>A> 9073933	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	>A> 9073933	Mar 30, 2025	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023			U-1658	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	>A> 9066980	Jan 30, 2024	DP U-528			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006					I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	9040085	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9045519	Jun 22, 2019	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					PC	Nov 28, 2015
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2016	DS DP U-1115			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	>A> 9079912	Dec 12, 2026	U-1573			
	>A> 9079912	Dec 12, 2026	U-1721			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	>A> 7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	>A> 7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	>A> 7468390	Nov 27, 2023	DP		>A> NCE	Jul 07, 2020
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9040562	Jul 28, 2026	DS DP U-1467			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					>A> ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					>A> ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					>A> ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					>A> ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					>A> ODE	May 28, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
<u>SOFOBUVIR - SOVALDI</u>						
N 204671 001	>A> 9085573	Mar 21, 2028	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001				>A> NCE		Jul 24, 2020
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	>A> 8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001				>A> ODE		Jul 10, 2022
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002				>A> ODE		Jul 10, 2022
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003				>A> ODE		Jul 10, 2022
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9060995	Jan 25, 2033	U-1710			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
	>A> 9060992	Nov 01, 2025	U-1320			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8992989	Nov 16, 2027	DP U-1675			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001 >A>	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002 >A>	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003 >A>	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004 >A>	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005 >A>	9101545	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001 >A>	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002 >A>	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003 >A>	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004 >A>	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>